[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 594
1. Ossareh S, Shooshtarizadeh T, Naseem S: An unusual case of posttransplant osteoid osteoma. Exp Clin Transplant; 2009 Jun;7(2):137-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplant tumors are one of the important long-term complications of renal transplant.
  • However, aside from noninvasive Kaposi sarcomas, increased production of benign tumors has not been observed after renal transplantation, and to our knowledge, no cases of posttransplant osteoid osteoma have been reported so far.
  • Osteoid osteoma is a common, benign, bone neoplasm that occurs typically in the long bones and presents with severe, intractable pain.
  • Here, we present a 49-year-old man, who presented with increasing bone pain in the right upper arm, 7 months after a renal transplant.
  • Despite an initial normal right humerus radiograph, a raised subperiosteal tumor was diagnosed in the medial border of the right humerus a few months later.
  • The patient's pain, which had been resistant to most analgesics, completely disappeared after surgery, and he is currently devoid of any lesions, 9 months after excision of the tumor.
  • [MeSH-major] Bone Neoplasms / radiography. Humerus / radiography. Kidney Transplantation / adverse effects. Osteoma, Osteoid / radiography

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715521.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Ethmoidal osteoid osteoma with orbital and intracranial extension - a case report. BMC Ear Nose Throat Disord; 2005 Mar 11;5:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteoid osteoma is a benign bone neoplasm which is seen in the long bones of appendicular skeleton.
  • Radical excision of the tumor could thus be achieved through a craniofacial approach.
  • CONCLUSION: Although benign and rare, skull base osteoid osteoma can present with neurological deficit due to its mass effect and involvement of vital structures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1998 Apr;12(2):173-5 [11013675.001]
  • [Cites] Am J Clin Pathol. 1975 Mar;63(3):391-6 [1115044.001]
  • [Cites] J Laryngol Otol. 1989 Jun;103(6):634-7 [2769039.001]
  • (PMID = 15760476.001).
  • [ISSN] 1472-6815
  • [Journal-full-title] BMC ear, nose, and throat disorders
  • [ISO-abbreviation] BMC Ear Nose Throat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC555567
  •  go-up   go-down


3. Riddle ND, Yamauchi H, Caracciolo JT, Cheong D, Khakpour N, Bui MM: Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature. Cases J; 2010;3:51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature.
  • INTRODUCTION: Giant cell tumor (GCT) is an aggressive, but usually benign bone neoplasm most commonly arising in the metaphysis/epiphyses of long bones.
  • While they are categorized as benign tumors, they can be locally aggressive and clinically have metastatic potential.
  • The most common locations of this tumor include the distal femur, proximal tibia, and distal radius.
  • No chondroid or osseous elements were present.
  • CONCLUSION: The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the diagnosis of giant cell tumor.
  • Resection of tumor was performed.
  • This case is important as it shows where the physician must keep this diagnosis in mind whenever a deeply located breast mast is present.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1992;21(7):482-8 [1439904.001]
  • [Cites] Respir Med. 1991 Sep;85(5):435-6 [1759012.001]
  • [Cites] J Surg Oncol. 1989 Feb;40(2):128-31 [2492623.001]
  • [Cites] Intern Med. 2007;46(14):1151-2 [17634719.001]
  • [Cites] Skeletal Radiol. 2003 Feb;32(2):107-10 [12589492.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):351-5 [12746169.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):231-2 [10738893.001]
  • (PMID = 20205847.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825505
  •  go-up   go-down


Advertisement
4. Fu K, Meng ZB, Li J, Li HC: [Repairing the defect of benign bone tumor with the coralline hydroxyapatite]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May;33(5):421-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing the defect of benign bone tumor with the coralline hydroxyapatite].
  • OBJECTIVE: To observe the clinical effect of repairing bone defectin post-operation benign tumor with coralline hydroxyapatite(CHAP).
  • The CHAP was implanted into the lesion after bone tumor curettage to 25 patients.
  • The sizes of bone defect ranged from 0.8 cm x 0.5 cm x 0.5 cm to 10 cm x 3.5 cm x 2 cm.
  • X-ray showed that there was osteogenesis at the cortical bone 1 month post-operation.
  • There is corresponding synchronization between bone formation with CHAP biodegradation.
  • The CHAP is an excellent bone defect repairing material.
  • [MeSH-major] Bone Neoplasms / surgery. Ceramics. Giant Cell Tumor of Bone / surgery. Hydroxyapatites. Prostheses and Implants
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Regeneration. Bone Substitutes. Child. Female. Femur / surgery. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544846.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Hydroxyapatites; 0 / coralline hydroxyapatite
  •  go-up   go-down


5. Li J, Wang ZQ, Zhang YM, Song HP, Yuan L: [Application of allogeneic bone in surgical treatment of benign bone neoplasm]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul;26(7):987-90
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of allogeneic bone in surgical treatment of benign bone neoplasm].
  • OBJECTIVE: To evaluate the clinical outcomes of allogeneic bone grafting for bone defect resulting from benign neoplasm resection and discuss the clinical application and bone defect repair mechanisms of allogeneic bone.
  • METHODS: A retrospective review was conducted of 135 patients with benign neoplasm resection who received bone defect filling with the allogeneic bone graft.
  • RESULTS: In the 104 patients with complete clinical follow-up data, 96 achieved bone union, 7 experienced relapses to require surgical intervention and 1 had severe infection to lead to failure of the operation.
  • The mean time for bone union was 9.7 months, and during the follow-up, no viral disease in relation to the graft was found after surgery.
  • CONCLUSION: Bone defect filling with allogeneic bone graft can be simple and safe in comparison with that with autograft or other biomaterials, and the bone healing time, infection rate and local tumor recurrence can be comparable with the autograft.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864094.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Stănescu L, Popescu CF, Niculescu CE, Dumitrescu D, Mogoantă SS, Georgescu I: Subungual exostosis of the big toe. Rom J Morphol Embryol; 2009;50(3):501-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The subungual exostosis is a benign bone tumor on the distal phalanx of a digit, beneath or adjacent to the nail, often bringing in discussion many differential diagnosis.
  • In the present, the radiological findings of the affected finger and the histopathological ones from the fragment excised confirmed the diagnosis of subungual exostosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690782.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


7. Fukunaga S, Futani H, Yoshiya S: Endoscopically assisted resection of a scapular osteochondroma causing snapping scapula syndrome. World J Surg Oncol; 2007;5:37
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteochondroma is the most common benign bone tumor in the scapula.
  • Removal of the tumor was performed by the use of endoscopically assisted resection.
  • The tumor was resected in a piece-by-piece manner by the use of graspers through the same portal.
  • CT images showed complete tumor resection.
  • [MeSH-major] Bone Neoplasms / surgery. Endoscopy. Osteochondroma / surgery. Scapula

  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Phys Med Rehabil. 1997 May;78(5):506-11 [9161370.001]
  • [Cites] J Shoulder Elbow Surg. 1999 Jan-Feb;8(1):53-7 [10077798.001]
  • [Cites] Clin Orthop. 1961;20:139-50 [13770600.001]
  • [Cites] Orthopedics. 2005 Feb;28(2):171-2 [15751374.001]
  • [Cites] Acta Orthop Scand. 1999 Aug;70(4):394-6 [10569273.001]
  • [Cites] J Pediatr Orthop. 1995 Sep-Oct;15(5):578-81 [7593565.001]
  • [Cites] Arthroscopy. 2002 May-Jun;18(5):23E [11987048.001]
  • [Cites] Clin Orthop Relat Res. 1968 May-Jun;58:105-15 [4299856.001]
  • [Cites] J Bone Joint Surg Br. 1973 May;55(2):345-9 [4707302.001]
  • [Cites] Arthroscopy. 1995 Feb;11(1):106-11 [7727002.001]
  • [Cites] Arthroscopy. 1995 Feb;11(1):52-6 [7727012.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1729-35 [10845514.001]
  • (PMID = 17378939.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839090
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


8. Manjunatha BS, Nagarajappa D: Osteoid osteoma. Indian J Dent Res; 2009 Oct-Dec;20(4):514-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma is a benign tumor of the bone which arises from osteoblasts and is extremely rare in jaws.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Osteoma, Osteoid / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Fibroma, Ossifying / diagnosis. Humans. Mandibular Diseases / diagnosis. Osteitis / diagnosis. Osteoblastoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139585.001).
  • [ISSN] 1998-3603
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Liu H, Sun J, Wang Y, Yang X, Zhu E: [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Nov;22(11):1349-53
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repairing bone defects of benign bone neoplasm by grafting of bioactive glass combined with autologous bone marrow].
  • OBJECTIVE: To investigate the clinical application of grafting with bioactive glass (BG) and autologous bone marrow for defect after resection and curettage of benign bone neoplasm.
  • METHODS: From January 2004 to May 2007, 34 patients with bone defects were repaired.
  • There were 14 cases of simple bone cysts, 6 cases of fibrous dysplasia, 3 cases of osteoid osteoma, 4 cases of non-ossifying fibroma, 2 cases of enchondroma and 3 cases of giant cell tumor of bone.
  • Tumor sizes varied from 2.0 cm x 1.5 cm x 1.0 cm to 9.0 cm x 3.0 cm x 2.5 cm.
  • Benign bone neoplasm was removed thoroughly with a curet or osteotome, bone defects ranged from 3.0 cm x 2.0 cm x 1.5 cm to 11.0 cm x 3.5 cm x 3.0 cm, which was closed-up with the mixtures of BG and autogenous red bone marrow.
  • The postoperative systemic and local reactions were observed, and the regular X-ray examinations were performed to observe the bone healing.
  • At averaged 16 weeks after operation, patients with bone tumor in lower limbs resumed walking independently and those with bone tumor in upper limbs resumed holding object.
  • There was no tumor recurrence during follow-up.
  • Radiographically, the interface between the implanted bone and host bone became fuzzy 1 month after implantation.
  • Two months after operation, the BG was absorbed gradually, new bone formation could be seen in the defects.
  • Four months after operation, implanted bone and host bone merged together, bone density increased.
  • Six to ten months after operation, the majority of the implanted BG was absorbed and substituted for new bone, bone remodeling was established.
  • CONCLUSION: BG may boast both bone conductive and bone inductive activities.
  • The combined grafting with BG and autologous bone marrow appears to be minimally invasive treatment to repair bone defects of benign bone neoplasm, with rare complications and no significant reverse reaction, and could repair bone defects completely.
  • [MeSH-major] Bone Marrow Transplantation. Bone Substitutes. Postoperative Complications / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / surgery. Bone and Bones / pathology. Child. Female. Follow-Up Studies. Glass. Humans. Male. Middle Aged. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068605.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes
  •  go-up   go-down


10. Cabrera RA, Almeida M, Mendonça ME, Frable WJ: Diagnostic pitfalls in fine-needle aspiration cytology of temporomandibular chondroblastoma: report of two cases. Diagn Cytopathol; 2006 Jun;34(6):424-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondroblastoma is a benign bone neoplasm, which usually presents in the epiphysis of long bones, but can occur in unusual locations.
  • This emphasizes the diagnostic pitfalls of this entity and expands the cytologic differential diagnosis of tumors of the parotid region.
  • [MeSH-major] Biopsy, Fine-Needle. Bone Neoplasms / diagnosis. Chondroblastoma / diagnosis. Mandible / pathology. Temporal Bone / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Parotid Neoplasms / pathology. Synovitis, Pigmented Villonodular / pathology

  • Genetic Alliance. consumer health - Chondroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680777.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Layadi F, Aniba K, Lmejjati M, Aït Elqadi A, Aït Benali S: [Giant osteoid osteoma of the posterior skull base. A case report and literature review]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):128-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ostéome ostéoïde géant de l'étage postérieur de la base du crâne. A propos d'un cas et revue de la littérature.
  • BACKGROUND: Osteoid osteoma is a benign bone neoplasm which is seen in the long bones.
  • Cerebral MRI shows a giant lesion of the posterior cerebral fossa with destruction of the left petrous bone and the left side of the occipital bone.
  • CONCLUSION: Although benign and rare, osteoid osteoma can present with neurological deficit due to mass effect and involvement of nervous structures especially in the posterior skull base.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840973.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Arpino L, Gragnaniello C, Nina P, Franco A: Limited approach to a thoracic spine osteoblastoma. J Neurosurg Sci; 2008 Dec;52(4):123-5; discussion 125
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoblastoma (OB) is a rare primary benign bone tumor.
  • The peak incidence of this neoplasm is in the first two decades of life.
  • It is important to differentiate OB from osteoid osteoma, a very similar bone tumor.
  • OB is rare benign bone neoplasm that generally affect the posterior elements of the spine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981987.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Altay M, Bayrakci K, Yildiz Y, Erekul S, Saglik Y: Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci; 2007 Sep;12(5):415-23
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients.
  • BACKGROUND: Secondary malignancies arising from benign bone tumors are rare.
  • Their recognition and diagnosis are difficult, and their slow growth and late recurrence require long-term follow-up.
  • In this study, malignant transformation rates of various histological types of benign cartilage-forming bone tumors in large series were evaluated.
  • METHODS: Between 1986 and 2004, a retrospective analysis of 627 cartilage-forming benign bone tumors revealed that 32 patients had malignant transformation.
  • RESULTS: The rate of malignant transformation for cartilage-originating tumors was 5.1% (solitary osteochondromas 4.2%, multiple osteochondromas 9.2%, solitary enchondromas 4.2%).
  • The average time between the initial diagnosis and malignant transformation was 9.8 years.
  • The tumors generally were well differentiated.
  • Five patients (15.6%) died of tumor recurrence or metastasis at an average of 20.6 months.
  • One patient is alive with tumor at 104 months.
  • CONCLUSIONS: Cartilage-forming benign bone tumors are rather prone to undergo malignant transformation.
  • Although malignant transformation of a benign bone tumor is a rarely encountered situation, orthopedic surgeons should be cautious while following patients with a benign bone neoplasm.
  • [MeSH-major] Bone Neoplasms / pathology. Cartilage / pathology. Chondrosarcoma / secondary. Neoplasms, Second Primary / pathology. Osteochondroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909925.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Moore T, McLain RF: Image-guided surgery in resection of benign cervicothoracic spinal tumors: a report of two cases. Spine J; 2005 Jan-Feb;5(1):109-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided surgery in resection of benign cervicothoracic spinal tumors: a report of two cases.
  • BACKGROUND CONTEXT: Osseous spinal tumors are an uncommon cause of persistent axial pain and muscle spasm, but even benign lesions may grow to cause deformity or neurological signs.
  • Traditional treatment approaches to resection can be debilitating even when the tumor is benign.
  • PURPOSE: Emerging technologies allow surgeons to diagnose and treat osseous neoplasms while minimizing the collateral damage caused by surgical exposure and tumor excision.
  • STUDY DESIGN: Technical considerations are presented through two cases of benign osseous neoplasm occurring in the cervicothoracic spine of competitive athletes, demonstrating the meth-ods used to provide effective treatment while maintaining maximal functional capacity.
  • METHODS: Stereotactic imaging and intraoperative guidance was used as an adjunct to tumor care in these patients.
  • Used in combination with minimally invasive, microsurgical techniques,stereotactic guidance localized and verified excision margins of benign vertebral lesions, minimizing soft tissue trauma and collateral damage.
  • CONCLUSIONS: Image guidance can accurately localize and guide excision of benign vertebral lesions while minimizing soft tissue trauma and collateral damage, allowing patients a rapid and complete return to high-demand function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739278.001).
  • [ISSN] 1529-9430
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Daghfous M, Charfi H, Turki M, Maalla R, Baccari S, Tarhouni L: [Chondromyxoid fibroma. A case report of location in the phalanx of the thumb]. Chir Main; 2007 Jun;26(3):159-64
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondromyxoid Fibroma is a rare benign osseous tumor especially in the hand, because the hand represents less than 3% of all osseous locations.
  • It can causes problems of differential diagnosis with several types of tumors and in particular with chondrosarcoma, for which the management is totally different.
  • We report a case of location of a chondromyxoid fibroma in a phalanx of the thumb, which caused problems of differential diagnosis with chondroma and chondrosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Chondroblastoma / pathology. Fibroma / pathology. Thumb / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590372.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Fine HF, Ferrara DC, Ho IV, Takahashi B, Yannuzzi LA: Bilateral choroidal osteomas with polypoidal choroidal vasculopathy. Retin Cases Brief Rep; 2008;2(1):15-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A choroidal osteoma is a benign osseous tumor typically arising in the juxtapapillary or peripapillary area.
  • To our knowledge, this variant form of vasogenesis has not previously been described in association with this tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25389606.001).
  • [ISSN] 1935-1089
  • [Journal-full-title] Retinal cases & brief reports
  • [ISO-abbreviation] Retin Cases Brief Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Tamai N, Myoui A, Kudawara I, Ueda T, Yoshikawa H: Novel fully interconnected porous hydroxyapatite ceramic in surgical treatment of benign bone tumor. J Orthop Sci; 2010 Jul;15(4):560-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel fully interconnected porous hydroxyapatite ceramic in surgical treatment of benign bone tumor.
  • BACKGROUND: Large bone defects remaining after curettage of benign bone tumors should be filled with a substitute to restore mechanical strength.
  • In 2000, we developed a fully interconnected porous calcium hydroxyapatite ceramic (IPCHA, NEOBONE) and have utilized it as a bone substitute.
  • The large interconnecting channels (average diameter 40 microm) permit easy penetration of tissue into the deep pores, so IP-CHA can itself induce local bone repair processes.
  • The purpose of this study was to evaluate the clinical outcomes with the use of IP-CHA as bone substitute after curettage of benign bone tumors.
  • METHODS: We reviewed the results of 71 patients with benign bone tumors sequentially treated by curettage followed by implantation of IP-CHA between 2000 and 2006.
  • Radiographic findings were classified into five stages: stage 0, no change; stage 1, slight bone formation; stage 2, moderate bone formation; stage 3, consolidation; stage 4, absorption.
  • However, there were 10 local recurrences, which is similar to the recurrence rate for such tumors treated with or without implantation of CHAs and reflects the biological nature of each tumor.
  • CONCLUSIONS: In this study, we utilized IP-CHA as a bone substitute after curettage of benign bone tumors and demonstrated its usefulness in the clinical situation.
  • IP-CHA comparatively exhibited excellent bone formation at an early stage although the problem of recurrence of the tumor remained.
  • We conclude that IP-CHA is a useful bone substitute for the treatment of benign bone tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Ceramics / therapeutic use. Durapatite / therapeutic use. Osteogenesis
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Substitutes / therapeutic use. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. HYDROXYAPATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721726.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Substitutes; 91D9GV0Z28 / Durapatite
  •  go-up   go-down


18. Yanagawa T, Watanabe H, Shinozaki T, Takagishi K: Curettage of benign bone tumors without grafts gives sufficient bone strength. Acta Orthop; 2009 Feb;80(1):9-13
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curettage of benign bone tumors without grafts gives sufficient bone strength.
  • BACKGROUND AND PURPOSE: The defect that results after curettage of a bone tumor is usually filled in the same way.
  • We report the outcome in patients with benign bone tumors that were treated with curettage but no filling.
  • PATIENTS AND METHODS: We retrospectively studied 78 patients (mean age at the time of operation was 27 (6-73) years, 44 men) who had had a benign bone tumor curetted with no filling of the defect.
  • The commonest tumor types were giant cell tumor of bone (27), fibrous dysplasia (13), enchondroma (9), and simple bone cyst (7).
  • Local recurrence occurred in 9 patients; 7 of them had a giant cell tumor.
  • INTERPRETATION: Routine filling of curetted bone lesions does not appear to be necessary from a mechanical point of view.
  • [MeSH-major] Bone Neoplasms / surgery. Curettage / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Cysts / surgery. Bone Remodeling / physiology. Follow-Up Studies. Giant Cell Tumor of Bone / surgery. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Knee. 2002 Feb;9(1):73-5 [11830385.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Orthop Sci. 2002;7(2):194-8 [11956979.001]
  • [Cites] J Hand Surg Br. 2002 Oct;27(5):446-51 [12367544.001]
  • [Cites] Biomaterials. 2003 Jul;24(16):2739-47 [12711520.001]
  • [Cites] Arch Orthop Trauma Surg. 2004 Jun;124(5):301-5 [15014954.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jul;86(5):719-25 [15274270.001]
  • [Cites] J Bone Joint Surg Am. 1981 Mar;63(3):367-75 [7204433.001]
  • [Cites] Clin Orthop Relat Res. 1985 Jan-Feb;(192):149-58 [3967417.001]
  • [Cites] Acta Orthop Scand. 1984 Dec;55(6):597-600 [6524324.001]
  • [Cites] Z Kinderchir. 1985 Aug;40(4):217-20 [3864319.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1988 Jan;(226):299-310 [3335103.001]
  • [Cites] Arch Orthop Trauma Surg. 1989;108(5):296-9 [2675797.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):189-90 [2249528.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):212-3 [2249537.001]
  • [Cites] J Hand Surg Am. 1991 Jan;16(1):139-42 [1995672.001]
  • [Cites] Arch Orthop Trauma Surg. 1992;111(2):61-5 [1562425.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] Calcif Tissue Int. 1995 Jul;57(1):64-8 [7671168.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):245-50 [7497676.001]
  • [Cites] Arch Orthop Trauma Surg. 1996;115(1):45-8 [8775710.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Acta Orthop Scand. 1999 Jun;70(3):308-15 [10429612.001]
  • [Cites] Biomaterials. 2007 Jan;28(3):400-4 [17010424.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):510-3 [16736145.001]
  • [Cites] Acta Orthop. 2008 Feb;79(1):86-93 [18283578.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):4-8 [19234881.001]
  • [CommentIn] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • (PMID = 19234882.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Other-IDs] NLM/ PMC2823236
  •  go-up   go-down


19. Li Y, Liang Q, Wen YQ, Chen LL, Wang LT, Liu YL, Luo CQ, Liang HZ, Li MT, Li Z: Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet; 2010 Apr 15;198(2):97-106
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
  • Proteins extracted from osteosarcoma tissue and benign bone tumors, including osteoblastoma, chondroblastoma, and giant cell tumor of bone, were examined using two-dimensional gel electrophoresis followed by mass spectrometry analysis and database searches.
  • Aberrant expression of cytoskeletal- and microtubule-associated proteins in osteosarcoma may provide an advantage for tumor invasion and metastasis by affecting the stability of microtubule, which consequently influences the prognosis of patients.
  • [MeSH-major] Bone Neoplasms / metabolism. Neoplasm Proteins / analysis. Osteoblastoma / metabolism. Osteosarcoma / metabolism. Proteomics / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Bone and Bones / metabolism. Bone and Bones / pathology. Child. Chondroblastoma / metabolism. Chondroblastoma / pathology. Female. Giant Cell Tumor of Bone / metabolism. Giant Cell Tumor of Bone / pathology. Humans. Male. Middle Aged. Proteome / analysis. Proteome / metabolism. Young Adult


20. Taleb C, Gouzou S, Mantovani G, Liverneaux P: Treatment of benign bone tumours of the hand using osteoscopy. Chir Main; 2010 Apr;29(2):78-81
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of benign bone tumours of the hand using osteoscopy.
  • Curettage and bone grafting are used traditionally to treat benign bone tumours of the hand.
  • This is a report on three benign metacarpal bone tumours treated with three different endoscopic approaches: multiportal, extended uniportal and oblique uniportal.
  • In theory, the multiportal approach has several drawbacks: weakening of the bone cortex, a limited visual field and seepage of injectable phosphocalcic cement.
  • The oblique uniportal approach seems less troublesome; vision of the bone cavity is good, curettage of the tumour is complete, the bone cortex is undamaged and there is no leakage of injectable phosphocalcic cement.
  • All things considered, the oblique osteoscopic uniportal approach seems to be the best option for the management of benign bone tumours of the hand.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods. Curettage / methods. Endoscopy / methods. Metacarpal Bones
  • [MeSH-minor] Adult. Bone Cements / therapeutic use. Bone Diseases, Developmental / surgery. Chondroma / surgery. Clinical Protocols. Female. Fluoroscopy. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20153235.001).
  • [ISSN] 1769-6666
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


21. Blackwell JB, Curnow MN: Benign bone tumours in Western Australia, 1972-1996. Pathology; 2007 Dec;39(6):567-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign bone tumours in Western Australia, 1972-1996.
  • AIMS: To review the benign bone tumours accessioned by the Bone Tumour Registry (BTR) of Western Australia (WA) during the years 1972-1996 and to determine the incidence of the more common types.
  • RESULTS: During the 25 year period, 849 benign tumours were accessioned and incidence rates have been calculated for 86 chondromas, 68 osteoid osteomas, 47 giant cell tumours, 32 chondroblastomas, 15 periosteal chondromas and 13 chondromyxoid fibromas.
  • CONCLUSION: The BTR provides a valuable resource for the study of primary bone tumours.
  • This review has established reliable incidence rates for the six most common benign tumours.
  • Such information is rarely available for benign tumours.
  • [MeSH-major] Bone Neoplasms / pathology. Registries
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Western Australia / epidemiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027260.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Demichev NP, Dianov SV: [Cryodestruction for preventing the recurrence of benign bone tumors]. Vopr Onkol; 2008;54(5):592-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryodestruction for preventing the recurrence of benign bone tumors].
  • The paper discusses data on the destructive influence of super low temperatures on tissue of benign bones tumors from 91 patients.
  • It may be used in clinical practice as an additional means of improving ablasticity of bone resection.
  • [MeSH-major] Bone Neoplasms / prevention & control. Cryosurgery. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069472.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


23. Panagopoulos I, Mertens F, Löfvenberg R, Mandahl N: Fusion of the COL1A1 and USP6 genes in a benign bone tumor. Cancer Genet Cytogenet; 2008 Jan 1;180(1):70-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion of the COL1A1 and USP6 genes in a benign bone tumor.
  • Aneurysmal bone cyst (ABC) is a benign intraskeletal cyst that often expands rapidly and shows a strong tendency to recur.
  • Here we report a second case of a bone tumor carrying a t(17;17) resulting in a COL1A1-USP6 chimeric gene.
  • [MeSH-major] Bone Neoplasms / genetics. Collagen Type I / genetics. Gene Fusion. Proto-Oncogene Proteins / genetics. Tibia. Translocation, Genetic. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Adolescent. Chromosomes, Human, Pair 17. Humans. Male. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068538.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Proto-Oncogene Proteins; 0 / collagen type I, alpha 1 chain; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


24. Angiero F, Mellone P, Baldi A, Stefani M: Osteoblastoma of the jaw: report of two cases and review of the literature. In Vivo; 2006 Sep-Oct;20(5):665-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoblastoma is a benign bone tumor of osteoblastic origin.
  • Both tumors were resected with wide surgical margins and neither patient had adjuvant radiation or chemotherapy.
  • Differential diagnosis and immunohistochemical features potentially useful for refining diagnosis of osteoblastoma are also discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Jaw Neoplasms / pathology. Osteoblastoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091775.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Miyake A, Morioka H, Yabe H, Anazawa U, Morii T, Miura K, Mukai M, Takayama S, Toyama Y: A case of metacarpal chondrosarcoma of the thumb. Arch Orthop Trauma Surg; 2006 Aug;126(6):406-10
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enchondroma is the most common primary benign bone tumor of the hand.
  • It often is difficult to make a histological distinction between benign cartilaginous tumors and low-grade chondrosarcomas, because enchondromas at this site often show histological features suggestive of malignancy.
  • This is a case report of chondrosarcoma affecting the metacarcal bone of the thumb, treated by en block resection and preserving the function of the thumb by bone graft reconstruction, with reference to the literature.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. Metacarpal Bones

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557368.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Forsyth RG, De Boeck G, Bekaert S, De Meyer T, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: Telomere biology in giant cell tumour of bone. J Pathol; 2008 Apr;214(5):555-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere biology in giant cell tumour of bone.
  • Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases.
  • GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance.
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumors / genetics. Telomere / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Microscopy, Confocal. Middle Aged. Neoplasm Proteins / metabolism. Nuclear Proteins / metabolism. Osteoclasts / metabolism. Osteoclasts / pathology. Phosphoproteins / metabolism. RNA-Binding Proteins / metabolism. Telomerase / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland
  • (PMID = 18278785.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / nucleolin; 143220-95-5 / PML protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Thomas EO, Gordon J, Smith-Thomas S, Cramer SF: Diffuse uterine leiomyomatosis with uterine rupture and benign metastatic lesions of the bone. Obstet Gynecol; 2007 Feb;109(2 Pt2):528-30
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse uterine leiomyomatosis with uterine rupture and benign metastatic lesions of the bone.
  • BACKGROUND: We report a case of diffuse uterine leiomyomatosis in pregnancy complicated by uterine rupture and dissemination to the bone.
  • A free-air series performed postoperatively to confirm paralytic ileus revealed multiple lytic bone lesions.
  • The diagnosis of diffuse uterine leiomyomatosis with metastasis was made on histology of the resected uterus and fine-needle aspiration biopsy of the bone.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fetal Death. Leiomyomatosis / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Prenatal Diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Hysterectomy. Neoplasm Metastasis. Pregnancy. Pregnancy Trimester, First. Tomography, X-Ray Computed. Uterine Rupture

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267884.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Pans S, Brys R, Van Breuseghem I, Geusens E: Benign bone tumours of the spine. JBR-BTR; 2005 Jan-Feb;88(1):31-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign bone tumours of the spine.
  • A wide variety of primary bone tumours can involve the spine.
  • We present an overview of the primary benign bone tumours of the spine.
  • [MeSH-major] Magnetic Resonance Imaging. Spinal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Spinal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792167.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 16
  •  go-up   go-down


29. Carter T, Flik K, Boland P, Kennedy JG: Iliac hematoma mimicking neoplasm in adolescent athletes. Orthopedics; 2008 Nov;31(11):1144
MedlinePlus Health Information. consumer health - Sports Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iliac hematoma mimicking neoplasm in adolescent athletes.
  • However, the presentation of such injuries can at times be clinically indistinguishable from the onset of a benign or malignant neoplastic process.
  • This article presents the cases of 2 adolescent boys with traumatic injuries to the hip, in which the threat of neoplasm could not be ruled out by in both initial imaging studies.
  • The authors recommend a diagnostic algorithm to approach the differentiation of iliac hematoma from neoplasm and address the issue of waiting time in the diagnostic process.
  • Early-and if necessary repeated-biopsy to rule out these conditions is advised, as conclusive pathologic findings are the only evidence that can rule out Ewing's sarcoma or an aneurysmal bone cyst.
  • Careful observation in combination with radiographic findings can yield a successful diagnosis, but the orthopedic surgeon must carefully weigh the increased risk of tumor growth against the need for biopsy.
  • [MeSH-major] Athletic Injuries / diagnosis. Bone Neoplasms / diagnosis. Hematoma / diagnosis. Hip Injuries / diagnosis. Ilium / pathology
  • [MeSH-minor] Adolescent. Algorithms. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19226079.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Castelnuovo P, Giovannetti F, Bignami M, Ungari C, Iannetti G: Open surgery versus endoscopic surgery in benign neoplasm involving the frontal sinus. J Craniofac Surg; 2009 Jan;20(1):180-3
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open surgery versus endoscopic surgery in benign neoplasm involving the frontal sinus.
  • Indeed, its anatomic opening (ostium) is strictly related to a complex ethmoidal structure prechamber mainly composed of the frontal recess.This constitutional feature makes the endoscopic approach more complex in comparison with other major sinuses treatment.In the following work, we present a systematization of surgical approach in relation to different pathologies, analyzing differences and results throughout the comparison of 2 groups: one treated with the endoscopic approach, and the other with open surgery.From these observations, we can assess that surgical approach choice must consider several parameters such as neoplasm localization, extension, dimension, and frontal recess anatomic features.
  • [MeSH-minor] Adult. Aged. Ethmoid Bone / pathology. Ethmoid Bone / surgery. Female. Follow-Up Studies. Hospitalization. Humans. Length of Stay. Magnetic Resonance Imaging. Male. Middle Aged. Mucocele / surgery. Nasal Cavity / pathology. Osteoma / surgery. Papilloma, Inverted / surgery. Paranasal Sinus Diseases / surgery. Patient Care Planning. Postoperative Complications. Tissue Adhesions / etiology. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165022.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Chakrapani SD, Grim K, Kaimaktchiev V, Anderson JC: Osteoblastoma of the spine with discordant magnetic resonance imaging and computed tomography imaging features in a child. Spine (Phila Pa 1976); 2008 Dec 1;33(25):E968-70
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY OF BACKGROUND DATA: Osteoblastoma is a rare benign tumor of bone that is known to incite a localized inflammatory response.
  • These inflammatory features can simulate malignant behavior on MRI and can lead to misdiagnosis and unnecessarily aggressive resection unless one recognizes the classic benign features on CT.
  • RESULTS: A 9-year-old girl with back pain receives an MRI of the lumbar spine demonstrating a sacral tumor with potentially malignant features including extensive marrow edema and enhancement.
  • A CT demonstrates a well-circumscribed lesion without lytic changes or malignant bone formation.
  • A benign lesion was favored given the CT features and conservative resection was performed.
  • Final pathologic diagnosis was osteoblastoma.
  • CONCLUSION: This case illustrates that the MRI findings for osteoblastoma can be misleading and caution should be used when evaluating benign tumors with known inflammatory responses on MRI.
  • CT features seem to more accurately reflect the true nature and extent of the tumor.
  • [MeSH-major] Magnetic Resonance Imaging. Osteoblastoma / diagnosis. Spinal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Inflammation / diagnosis. Inflammation / radiography. Inflammation / surgery. Lumbar Vertebrae / pathology. Lumbar Vertebrae / radiography. Lumbar Vertebrae / surgery

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050575.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Shimizu N, Sakata K, Yamamoto I: Benign osteoblastoma of the temporal bone: Case report and review of the literature. Surg Neurol; 2006 Nov;66(5):534-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign osteoblastoma of the temporal bone: Case report and review of the literature.
  • BACKGROUND: Benign osteoblastoma arising from the temporal bone is extremely rare in elderly patients.
  • We reviewed the literature on benign osteoblastoma of the temporal bone and now propose a new classification of this pathologic entity based on its anatomical location in the temporal bone.
  • Preoperative computed tomography showed a bony destructive isodensity mass with calcified component involving the temporal bone.
  • After preoperative embolization on the day before surgery, the patient underwent tumor removal via a left infratemporal approach under neuronavigated guidance.
  • The pathologic examination revealed a benign osteoblastoma.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteoblastoma / diagnosis. Temporal Bone / pathology. Temporal Bone / radiography
  • [MeSH-minor] Aged. Embolization, Therapeutic. Female. Fluorodeoxyglucose F18. Hearing Loss / etiology. Humans. Intraoperative Complications / prevention & control. Neoplasm, Residual. Neuronavigation. Neurosurgical Procedures. Positron-Emission Tomography. Postoperative Hemorrhage / prevention & control. Tinnitus / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084206.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


33. Ugur HC, Torun F, Kanpolat Y: Petrous bone osteoblastoma invading the cavernous sinus. J Clin Neurosci; 2005 May;12(4):489-92
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Petrous bone osteoblastoma invading the cavernous sinus.
  • A CT scan revealed a mass originating from the petrous part of the temporal bone with infiltration of the cavernous sinus.
  • The patient was operated and a subtotal excision of the tumor was achieved.
  • Pathological examination revealed benign osteoblastoma.
  • During an 18 year follow up period, no progression of tumor has been detected.
  • [MeSH-major] Bone Neoplasms / pathology. Cavernous Sinus / pathology. Osteoblastoma / pathology. Petrous Bone / pathology
  • [MeSH-minor] Female. Humans. Magnetic Resonance Spectroscopy / methods. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925793.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


34. Güneş D, Mutafoğlu-Uysal K, Sarialioğlu F, Cakmakçi H, Olgun N: Aneurysmal bone cyst of rib presenting as a huge chest wall mass. Turk J Pediatr; 2009 Jan-Feb;51(1):82-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysmal bone cyst of rib presenting as a huge chest wall mass.
  • Aneurysmal bone cyst is a rare benign tumor of the bone that can be difficult to distinguish from malignant tumors, especially when it presents in an unusual location.
  • Herein, we report a six-year-old girl with a primary aneurysmal bone cyst in an uncommon location.
  • She was successfully treated with total excision of tumor without any complication.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Ribs. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378899.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


35. Moskovszky L, Dezsö K, Athanasou N, Szendröi M, Kopper L, Kliskey K, Picci P, Sápi Z: Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Mod Pathol; 2010 Mar;23(3):359-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability.
  • Giant cell tumour of bone, a benign but potentially aggressive neoplasm, shows an increasing rate of chromosomal aneusomy that correlates with clinical course.
  • Mechanisms that generate chromosomal instability in giant cell tumour of bone are poorly understood.
  • To gain an insight into the possible mechanism for the generation of chromosomal instability in giant cell tumour of bone, we analysed 100 cases, including 57 primary nonrecurrent, 35 recurrent and 8 malignant giant cell tumour of bone cases. gamma-Tubulin immunohistochemistry was performed on tissue microarrays of 59 formalin-fixed paraffin-embedded cases, whereas pericentrin and gamma-tubulin fluorescent immunocytochemistry was carried out on 41 frozen smears.
  • Centrosome amplification was significantly higher in recurrent and malignant giant cell tumour of bones compared with nonrecurrent tumours (P<0.001).
  • These findings indicate that centrosome alteration and frequency of aneusomy correlate with clinical behaviour; the lack of an association between centrosome amplification and chromosome number alteration suggests that alternative causative mechanisms produce genetic instability in giant cell tumour of bone.
  • [MeSH-major] Bone Neoplasms / genetics. Centrosome / pathology. Chromosomal Instability. Giant Cell Tumor of Bone / genetics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062006.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Tubulin; 0 / pericentrin
  •  go-up   go-down


36. Ahrens WA, Ridenour RV 3rd, Caron BL, Miller DV, Folpe AL: GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol; 2008 Oct;39(10):1519-26
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms.
  • GLUT-1, an erythrocyte-type glucose transporter protein expressed in juvenile hemangiomas, has recently been shown to be a sensitive marker of perineurial cells and their tumors in a small number of cases.
  • Prompted by a recent report of GLUT-1 expression in epithelioid sarcoma, a tumor not generally felt to show perineurial differentiation, we examined GLUT-1 expression in a wide variety of mesenchymal tumors.
  • Sections from 247 mesenchymal tumors of a variety of histologic subtypes were retrieved from our archives and immunostained for GLUT-1 using heat-induced epitope retrieval and the DAKO ADVANCE detection system (DAKO, Carpinteria, CA).
  • All benign nerve sheath tumors showed a peripheral rim of positive normal perineurial cells, with 2 neurofibromas and 3 schwannomas showing more extensive staining.
  • GLUT-1 expression was also seen in a wide variety of benign and malignant mesenchymal tumors.
  • However, GLUT-1 expression was absent in nonjuvenile hemangioma endothelial tumors and in almost all low-grade lesions that enter the histologic differential diagnosis of perineurial tumors, including low-grade fibromyxoid sarcoma, dermatofibrosarcoma protuberans, and myxofibrosarcoma.
  • We conclude that GLUT-1 expression in mesenchymal tumors is by no means specific for perineurial differentiation, but may instead represent upregulation of this protein within hypoxic zones, secondary to upstream activation of proteins such as hypoxia-inducible factor 1-alpha.
  • [MeSH-major] Bone Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism. Mesenchymoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Count. Humans. Immunohistochemistry. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620729.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Neoplasm Proteins
  •  go-up   go-down


37. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • Bone marrow micrometastasis (BMM) is difficult to detect with routine methods.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


38. Haque AU, Moatasim A: Giant cell tumor of bone: a neoplasm or a reactive condition? Int J Clin Exp Pathol; 2008;1(6):489-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone: a neoplasm or a reactive condition?
  • Giant cell tumor of bone (GCTB) is a benign but locally aggressive bone tumor of young adults.
  • However such findings are not universal and can be seen in rapidly proliferating normal cells as well as in several osseous lesions of developmental and/or reactive nature, and the true neoplastic nature of GCTB remains controversial.
  • Malignancy usually does not occur in GCTB and when discover, it usually represents primary bone sarcomas missed at original diagnosis.
  • Aneurysmal bone cyst (ABC) shares many features with GCTB.
  • There had been unique karyotypic changes in some aneurysmal bone cysts making it distinct from GCTB.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):375-8 [12451570.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):297-307 [11193206.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):640-9 [10780856.001]
  • [Cites] J Postgrad Med. 1995 Jul-Sep;41(3):83-4 [10707722.001]
  • [Cites] Pathology. 1999 Nov;31(4):373-8 [10643009.001]
  • [Cites] Endocrinology. 1994 Jun;134(6):2416-23 [8194468.001]
  • [Cites] J Clin Invest. 1994 May;93(5):1959-67 [8182127.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1094-9 [7850706.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):465-71 [7526033.001]
  • [Cites] Nihon Seikeigeka Gakkai Zasshi. 1994 May;68(5):407-14 [7914219.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):856-67 [7943176.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Apr;31(2):89-94 [8471587.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):301-3 [8440744.001]
  • [Cites] J Cell Sci. 1992 Mar;101 ( Pt 3):681-6 [1522150.001]
  • [Cites] Lab Invest. 1992 Aug;67(2):166-74 [1501443.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):398-404 [1597517.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):523-6 [1562461.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):66-80 [1555533.001]
  • [Cites] Endocrinology. 1991 May;128(5):2324-35 [1850350.001]
  • [Cites] Endocrinol Jpn. 1990 Oct;37(5):741-7 [2086204.001]
  • [Cites] Acta Cytol. 1990 Nov-Dec;34(6):863-7 [2256421.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):59-75 [3006962.001]
  • [Cites] Nature. 1961 Apr 29;190:459-60 [13777407.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4353-63 [9751519.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Dec;55(12 Suppl 5):38-45 [9393425.001]
  • [Cites] J Pathol. 1985 Apr;145(4):297-305 [2987469.001]
  • [Cites] J Pathol. 1987 Oct;153(2):121-6 [2961857.001]
  • [Cites] Cell Tissue Res. 1985;241(3):671-5 [2992797.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1139-45 [2457425.001]
  • [Cites] Recent Prog Horm Res. 1989;45:507-27; discussion 527-31 [2682847.001]
  • [Cites] Endocrinology. 1988 Apr;122(4):1373-82 [3345718.001]
  • [Cites] Veroff Pathol. 1984;122:1-195 [6091360.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4141-5 [3300960.001]
  • [Cites] J Pathol. 1984 Dec;144(4):281-94 [6520652.001]
  • [Cites] J Cell Sci. 1984 Aug;70:61-71 [6501437.001]
  • [Cites] J Interferon Res. 1987 Oct;7(5):619-26 [3479501.001]
  • [Cites] J Oral Maxillofac Surg. 1986 Sep;44(9):708-13 [3462363.001]
  • [Cites] Endocrinology. 1986 Feb;118(2):824-8 [3455914.001]
  • [Cites] Am J Pathol. 1986 Feb;122(2):363-78 [3946557.001]
  • [Cites] J Bone Joint Surg Am. 1990 Feb;72(2):252-8 [1968067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3153-8 [2161750.001]
  • [Cites] Endocrinology. 1990 May;126(5):2733-41 [2184023.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2697-703 [2340469.001]
  • [Cites] Science. 1980 May 2;208(4443):516-8 [6154315.001]
  • [Cites] Int J Oral Surg. 1984 Apr;13(2):92-100 [6430822.001]
  • [Cites] Pathol Res Pract. 1984 May;178(5):431-40 [6462948.001]
  • [Cites] Calcif Tissue Int. 1980;31(1):29-34 [6770971.001]
  • [Cites] Pathol Res Pract. 1999;195(11):753-7 [10605695.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2896-902 [17653593.001]
  • [Cites] Bosn J Basic Med Sci. 2007 Feb;7(1):58-65 [17489771.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Sep-Oct;25(5):241-8 [17438664.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):484-9 [17013643.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1339-49 [16939392.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):151-8 [16825116.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):589-94 [16465417.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):32-6 [15860354.001]
  • [Cites] J Assoc Physicians India. 2004 Jul;52:585-6 [15645990.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] Ann Rheum Dis. 1996 Jun;55(6):388-95 [8694579.001]
  • [Cites] Cancer Genet Cytogenet. 1996 May;88(1):35-8 [8630976.001]
  • [Cites] Bone. 1995 Aug;17(2 Suppl):87S-91S [8579904.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Clin Orthop Relat Res. 1976 Oct;(120):201-31 [975659.001]
  • [Cites] N Engl J Med. 1974 Nov 14;291(20):1041-6 [4413338.001]
  • [Cites] Science. 1973 May 25;180(4088):875 [4706681.001]
  • [Cites] Science. 1975 Nov 21;190(4216):784-5 [1105786.001]
  • [Cites] J Exp Med. 1975 Sep 1;142(3):651-63 [1100763.001]
  • [Cites] J Bone Joint Surg Am. 1976 Jul;58(5):612-8 [932060.001]
  • [Cites] Nature. 1975 Nov 27;258(5533):325-7 [1196357.001]
  • [Cites] J Endocrinol. 1969 Nov;45(3):387-400 [5358264.001]
  • [Cites] J Pathol Bacteriol. 1966 Jul;92(1):163-7 [5956253.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Sep;8(5):316-21 [15480872.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):269-81, vi [15275686.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):983-93 [14608531.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):14-8 [14696139.001]
  • [Cites] Pathobiology. 2002-2003;70(6):333-42 [12865629.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • (PMID = 18787633.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480584
  • [Keywords] NOTNLM ; Giant cell tumor / aneurysmal bone cyst / bone / bone matrix / hemorrhage / osteoclast / osteoclastoma / telomerase
  •  go-up   go-down


39. Strobel K, Exner UE, Stumpe KD, Hany TF, Bode B, Mende K, Veit-Haibach P, von Schulthess GK, Hodler J: The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2008 Nov;35(11):2000-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.
  • OBJECTIVE: To evaluate the value of a dedicated interpretation of the CT images in the differential diagnosis of benign vs. malignant primary bone lesions with 18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT).
  • MATERIALS AND METHODS: In 50 consecutive patients (21 women, 29 men, mean age 36.9, age range 11-72) with suspected primary bone neoplasm conventional radiographs and 18F-FDG-PET/CT were performed.
  • Differentiation of benign and malignant lesions was separately performed on conventional radiographs, PET alone (PET), and PET/CT with specific evaluation of the CT part.
  • RESULTS: According to the standard of reference, conventional 17 lesions were benign and 33 malignant.
  • Median SUV(max) was 3.5 for benign lesions (range 1.6-8.0) and 5.7 (range 0.8-41.7) for malignant lesions.
  • In eight patients with bone lesions with high FDG-uptake (SUV(max) >or= 2.5) dedicated CT interpretation led to the correct diagnosis of a benign lesion (three fibrous dysplasias, two osteomyelitis, one aneurysmatic bone cyst, one fibrous cortical defect, 1 phosphaturic mesenchymal tumor).
  • In four patients with lesions with low FDG-uptake (SUV(max) < 2.5) dedicated CT interpretation led to the correct diagnosis of a malignant lesion (three chondrosarcomas and one leiomyosarcoma).
  • Combined PET/CT was significantly more accurate in the differentiation of benign and malignant lesions than PET alone (p = .039).
  • CONCLUSION: Dedicated interpretation of the CT part significantly improved the performance of FDG-PET/CT in differentiation of benign and malignant primary bone lesions compared to PET alone.
  • PET/CT more commonly differentiated benign from malignant primary bone lesions compared with conventional radiographs, but this difference was not significant.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone and Bones / pathology. Fluorodeoxyglucose F18. Image Processing, Computer-Assisted / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1996 Jul;200(1):243-7 [8657920.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):1124-8 [16985165.001]
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):22-30 [9933658.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):692-6 [16514531.001]
  • [Cites] Orthopedics. 1991 Aug;14 (8):891-4; discussion 894-5 [1656414.001]
  • [Cites] Radiologe. 1998 Apr;38(4):287-300 [9622823.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10 ):1695-701 [11038000.001]
  • [Cites] Skeletal Radiol. 2008 May;37(5):415-21 [18309481.001]
  • [Cites] Cancer. 2002 Jun 15;94(12 ):3277-84 [12115361.001]
  • [Cites] AJR Am J Roentgenol. 1982 Jul;139(1):45-8 [6283870.001]
  • [Cites] Nucl Med Commun. 2003 Nov;24(11):1139-43 [14569167.001]
  • [Cites] Mol Imaging Biol. 2008 Mar-Apr;10 (2):121-8 [18204955.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1508-12 [1869970.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1305-11 [11007511.001]
  • [Cites] Radiology. 2001 Jun;219(3):774-7 [11376267.001]
  • [Cites] J Nucl Med. 2007 Dec;48(12 ):1932-9 [18006618.001]
  • [Cites] J Nucl Med. 2006 May;47(5):885-95 [16644760.001]
  • [Cites] Radiology. 1988 Dec;169(3):805-10 [3055041.001]
  • [Cites] Eur Spine J. 1995;4(6):372-4 [8983661.001]
  • [Cites] Radiology. 2007 Dec;245(3):839-47 [18024454.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] Radiology. 1980 Mar;134(3):577-83 [6928321.001]
  • [Cites] J Nucl Med. 1988 Feb;29(2):181-6 [2831318.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] AJR Am J Roentgenol. 1982 Nov;139(5):943-8 [6981980.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):675-80 [11685032.001]
  • [Cites] J Orthop Sci. 2003;8(3):435-41 [12768492.001]
  • [Cites] Osteoporos Int. 2002 Sep;13(9):755-61 [12195540.001]
  • [Cites] Semin Musculoskelet Radiol. 2007 Dec;11(4):353-64 [18324599.001]
  • [Cites] Oncology (Williston Park). 2007 Feb;21(2):249-52 [17396486.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1836-9 [7562051.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):443-50 [16513614.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10 ):1637-43 [10520703.001]
  • [Cites] Radiology. 2007 Aug;244(2):566-74 [17641374.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] Skeletal Radiol. 2007 Jun;36 Suppl 1:S24-8 [16715239.001]
  • [Cites] Semin Nucl Med. 2006 Oct;36(4):286-94 [16950146.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1267-73 [16883004.001]
  • [Cites] Nucl Med Biol. 2004 Oct;31(7):875-82 [15464389.001]
  • (PMID = 18712385.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Rougraff BT: Bone graft alternatives in the treatment of benign bone tumors. Instr Course Lect; 2005;54:505-12
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone graft alternatives in the treatment of benign bone tumors.
  • Most bone grafting procedures are done during spinal fusion and to treat patients with skeletal trauma.
  • Very few studies have addressed the bone grafting of skeletal defects after benign bone tumor excision.
  • Contained defects have been treated with autogenous bone grafts, fresh-frozen allografts, freeze-dried allografts, demineralized bone matrix, and ceramic materials.
  • Additionally, bone morphogenetic proteins may provide a future treatment option for bone tumor reconstruction.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation / methods
  • [MeSH-minor] Bone Substitutes. Ceramics. Humans. Tissue Preservation / methods. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948475.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Substitutes
  • [Number-of-references] 30
  •  go-up   go-down


41. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • These tumors constitute a difficult clinical problem to handle.
  • By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts.
  • In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Long-term follow-up for patients with papillary thyroid carcinoma treated as benign nodules. Anticancer Res; 2007 Mar-Apr;27(2):1039-43
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for patients with papillary thyroid carcinoma treated as benign nodules.
  • BACKGROUND: The recent prevalence of ultrasonography and fine-needle aspiration biopsy (FNAB) has facilitated the detection and diagnosis of papillary thyroid carcinoma.
  • However, there are still cases that are preoperatively misdiagnosed and treated as benign nodules because ultrasonographic and FNAB findings do not provide sufficient evidence for a malignant diagnosis.
  • PATIENTS AND METHODS: We investigated the prognoses of 56 patients with papillary carcinoma who underwent thyroidectomy without node dissection under a diagnosis of benign nodules.
  • RESULTS: None of the patients underwent further surgery such as completion total thyroidectomy and node dissection after the pathological diagnosis of papillary carcinoma was established.
  • Two patients showed recurrence in the remnant thyroid and one showed recurrence in the bone.
  • CONCLUSION: Papillary carcinomas misdiagnosed as benign nodules on ultrasonography and FNAB are indolent and very slow-growing.
  • Immediate further surgery is not needed for such cases, even if they were resected as benign nodules at the initial surgery.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroid Nodule / diagnosis. Thyroid Nodule / surgery
  • [MeSH-minor] Adult. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Diagnostic Errors. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465240.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


43. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol; 2006 Feb;29(1):96-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of bone.
  • OBJECTIVE: To discuss the treatment and outcomes for giant cell tumor (GCT) of bone.
  • RESULTS: GCT is a rare benign bone lesion most often found in the extremities of women in the third and fourth decades of life.
  • Patients with extensive, recurrent, and/or biologically more aggressive tumors may require wide excision.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / surgery. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / surgery
  • [MeSH-minor] Curettage. Diagnosis, Differential. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462511.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


44. Karkuzhali P, Chithralekha S, Muthuvel E, Daniel RB: Chondromyxoid fibroma of the parietal bone. Neuropathology; 2005 Mar;25(1):84-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondromyxoid fibroma of the parietal bone.
  • We report the case of an 11-year old girl who presented with an intracranial chondromyxoid fibroma arising from parietal bone.
  • Chondromyxoid fibroma is a benign cartilaginous neoplasm, which can be easily mistaken for chondrosarcoma, especially in small biopsies.
  • To our knowledge, this is the second case of chondromyxoid fibroma reported to occur in parietal bone and is the first case reported in an English-language journal.
  • [MeSH-major] Chondroblastoma / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Dura Mater / pathology. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822822.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


45. Sciubba DM, Burdette EC, Cheng JJ, Pennant WA, Noggle JC, Petteys RJ, Alix C, Diederich CJ, Fichtinger G, Gokaslan ZL, Murphy KP: Percutaneous computed tomography fluoroscopy-guided conformal ultrasonic ablation of vertebral tumors in a rabbit tumor model. Laboratory investigation. J Neurosurg Spine; 2010 Dec;13(6):773-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous computed tomography fluoroscopy-guided conformal ultrasonic ablation of vertebral tumors in a rabbit tumor model. Laboratory investigation.
  • OBJECT: Radiofrequency ablation (RFA) has proven to be effective for treatment of malignant and benign tumors in numerous anatomical sites outside the spine.
  • The major challenge of using RFA for spinal tumors is difficulty protecting the spinal cord and nerves from damage.
  • However, conforming ultrasound energy to match the exact anatomy of the tumor may provide successful ablation in such sensitive locations.
  • In a rabbit model of vertebral body tumor, the authors have successfully ablated tumors using an acoustic ablator placed percutaneously via computed tomography fluoroscopic (CTF) guidance.
  • At 21 days, a bone biopsy needle was placed into the geographical center of the lesion, down which an acoustic ablator was inserted.
  • Three multisensor thermocouple arrays were placed around the lesion to provide measurement of tissue temperature during ablation, at thermal doses ranging from 100 to 1,000,000 TEM (thermal equivalent minutes at 43°C), and tumor volumes were given a tumoricidal dose of acoustic energy.
  • Pathological specimens were obtained to determine the extent of tumor death and surrounding tissue damage.
  • Measured temperature distributions were used to reconstruct volumetric doses of energy delivered to tumor tissue, and such data were correlated with pathological findings.
  • The CTF guidance provided accurate placement of the acoustic ablator in all tumors, as corroborated through gross and microscopic histology.
  • Significant tumor death was noted in all specimens without collateral damage to nearby nerve tissue.
  • Tissue destruction just beyond the margin of the tumor was noted in some but not all specimens.
  • CONCLUSIONS: Using a rabbit intravertebral tumor model, the authors have successfully delivered tumoricidal doses of acoustic energy via a therapeutic ultrasound ablation probe placed percutaneously with CTF guidance.
  • The authors have thus established the first technical and preclinical feasibility study of controlled ultrasound ablation of spinal tumors in vivo.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121752.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112852-03; United States / NCI NIH HHS / CA / R44 CA112852; United States / NCI NIH HHS / CA / R44 CA112852-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Adams SC, Potter BK, Robinson PG, Temple HT: Giant cell tumor of the distal femur associated with complete tumor necrosis. Orthopedics; 2010 Sep;33(9):688
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the distal femur associated with complete tumor necrosis.
  • Giant cell tumor is a benign tumor of bone with a predilection for juxta-articular locations.
  • Although not malignant, giant cell tumor often exhibits unpredictable and locally aggressive behavior, and in rare cases can metastasize in the absence of histologic malignancy.
  • Partial tumor necrosis has been infrequently reported within typical giant cell tumor.
  • A 17-year-old girl presented with a right distal femur giant cell tumor associated with complete tumor necrosis on histopathologic analysis.
  • The etiology, prevalence, and implications of complete necrosis in previously untreated giant cell tumor of bone remain unclear, as there are no previously published reports.
  • There were no radiographic signs of the necrotic tumor space remodeling with new bone.
  • The patient was treated with standard extended intralesional curetting through a generous cortical window permitting visualization of the entire lesion, and systematic high speed burring and thermal electrocautery ablation of the periphery, followed by micro particulate allogenic bone grafting.
  • At short-term follow-up, she had healed well with no evidence of tumor recurrence.
  • This article presents the first case, to our knowledge, of complete spontaneous tumor necrosis in a previously untreated bone giant cell tumor.
  • Increased understanding of spontaneous tumor necrosis associated with giant cell tumor may help guided future targeted medical and surgical treatment modalities.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 20839701.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • Lymphomas may clinically, radiologically, and morphologically mimic both benign and neoplastic conditions.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • In the first case, lymphoma occurred in a clinical setting where malignancy was unsuspected, highlighting the importance of careful morphologic evaluation of paucicellular samples, as well as awareness of rare clinicopathologic entities, in avoiding a misdiagnosis of a benign inflammatory infiltrate.
  • In the second case, the lymphoid neoplasm exhibited classic morphologic and immunophenotypic features, but presented at an unusual site of involvement.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


48. Sohn SH, Koh SA, Kim DG, Park SW, Lee KH, Kim MK, Choi JH, Hyun MS: A case of spine origin chondroblastoma metastasis to lung. Cancer Res Treat; 2009 Dec;41(4):241-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondroblastoma is a rare benign cartilaginous neoplasm that accounts for approximately 1% of all bone tumors and characteristically arises in the epiphysis of a long bone, particularly the humerus, tibia, and femur.
  • Unlike previously published examples of metastatic chondroblastoma, these metastasis developed before any operative manipulation of the primary tumor.
  • And primary tumor site was also unusual.
  • The histologic characteristics of the primary, metastatic tumors were those of a conventional chondroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1957 Nov;39-B(4):705-10 [13491633.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):721-6 [10524855.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):675-8 [9477099.001]
  • [Cites] Skeletal Radiol. 1995 Apr;24(3):220-2 [7610417.001]
  • [Cites] Hum Pathol. 1989 Oct;20(10):965-76 [2793161.001]
  • [Cites] J Pathol. 1999 Dec;189(4):463-9 [10629544.001]
  • [Cites] Am J Clin Pathol. 1987 Jul;88(1):1-9 [3604981.001]
  • [Cites] Pathol Res Pract. 1987 Feb;182(1):113-23 [3588400.001]
  • [Cites] Acta Orthop Scand. 1986 Aug;57(4):378-81 [3788507.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1770-89 [3978565.001]
  • [Cites] Clin Orthop Relat Res. 1977 Jul-Aug;(126):266-72 [598130.001]
  • [Cites] Pediatr Radiol. 1987;17(5):392-6 [3627860.001]
  • (PMID = 20057972.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2802843
  • [Keywords] NOTNLM ; Chondroblastoma / Lung metastasis / Spine origin
  •  go-up   go-down


49. Sierra RJ, Cabanela ME: Total hip arthroplasty in patients with underlying fibrous dysplasia. Orthopedics; 2009 May;32(5):320
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia is a developmental anomaly of bone formation that accounts for approximately 7% of benign bone tumors.
  • The results of THA in patients with this disorder is not known.
  • [MeSH-major] Arthroplasty, Replacement, Hip / instrumentation. Arthroplasty, Replacement, Hip / methods. Fibrous Dysplasia of Bone / complications. Fibrous Dysplasia of Bone / surgery. Hip Joint / surgery. Joint Instability / etiology. Joint Instability / surgery

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472968.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG: Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch Orthop Trauma Surg; 2009 Oct;129(10):1421-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Initial clinical impressions were of a benign bone tumor in 15 patients, fracture in 8, and infection in 3.
  • After initial inappropriate procedures, primary surgeons failed to send a tissue sample to a pathologist for definite diagnosis in 12 cases, and pathologists made incorrect diagnoses in the other 14.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280203.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Orhan Z, Oktas B, Yildirim U: An unusual presentation of peroneal neuropathy secondary to pigmented villonodular synovitis: a case report. Knee Surg Sports Traumatol Arthrosc; 2009 May;17(5):518-20
Genetic Alliance. consumer health - Synovitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pigmented villonodular synovitis (PVS) is a benign proliferative disorder of unknown origin that affects synovial joints, most commonly the knee.
  • Although this disease is categorized as an inflammatory process rather than a neoplasm, it may be locally destructive and involve muscles, tendons, bone and skin.
  • [MeSH-major] Peroneal Neuropathies / diagnosis. Peroneal Neuropathies / etiology. Synovitis, Pigmented Villonodular / complications. Synovitis, Pigmented Villonodular / diagnosis

  • Genetic Alliance. consumer health - Pigmented villonodular synovitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Knee. 2007 Oct;14 (5):390-4 [17600720.001]
  • [Cites] Arthroscopy. 2001 May;17(5):527-31 [11337722.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):548-50 [17148989.001]
  • [Cites] J Shoulder Elbow Surg. 2006 Nov-Dec;15(6):e8-10 [17126239.001]
  • [Cites] Arthroscopy. 2007 Apr;23(4):448.e1-3 [17418347.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14 (4):386-8 [17240150.001]
  • [Cites] Knee. 2007 Mar;14(2):99-106 [17161949.001]
  • [Cites] Clin Orthop Relat Res. 1996 Apr;(325):174-80 [8998871.001]
  • (PMID = 19205665.001).
  • [ISSN] 1433-7347
  • [Journal-full-title] Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
  • [ISO-abbreviation] Knee Surg Sports Traumatol Arthrosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Ramboaniaina S, Hoang DV, Berger M: [Aneurysmal carpal scaphoid cyst. A case report]. Chir Main; 2009 Feb;28(1):46-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cyst is a rare, benign bone tumor and its location in the carpal scaphoid has never been described in the literature.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Scaphoid Bone / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095484.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


53. Niethard M, Rogalski M, Deja M, Zacher J: [Partial physeal growth arrest with increasing genu varum deformity caused by a cortical enchondroma--a case report]. Z Orthop Unfall; 2008 Nov-Dec;146(6):725-9
Genetic Alliance. consumer health - Enchondroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The X-ray and MRI investigations have shown a benign lesion like osteofibroma of the mediodistal femur with an affection of the medial physis.
  • 1) resection of the benign lesion and arthroscopically assisted resection of the bony bar with fat-patch interposition;.
  • CONCLUSION: In cases of rare partial bridging of the physis induced by a benign bone tumour one can achieve early correction of axial deviation during growth with resection, interposition of a fat patch and temporary hemiepiphyseodesis.
  • [MeSH-major] Arthroscopy. Bone Malalignment / surgery. Bone Plates. Cartilage, Articular / surgery. Chondroma / surgery. Femur / surgery. Growth Plate / surgery. Knee Joint / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19085720.001).
  • [ISSN] 1864-6697
  • [Journal-full-title] Zeitschrift für Orthopädie und Unfallchirurgie
  • [ISO-abbreviation] Z Orthop Unfall
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Kitsoulis P, Galani V, Stefanaki K, Paraskevas G, Karatzias G, Agnantis NJ, Bai M: Osteochondromas: review of the clinical, radiological and pathological features. In Vivo; 2008 Sep-Oct;22(5):633-46
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common benign bone tumor and usually occurs in the metaphyseal region of the long bones.
  • This tumor takes the form of a cartilage-capped bony outgrowth on the surface of the bone.
  • Approximately 15% of osteochondromas occur as multiple lesions in the context of hereditary multiple osteochondromas (HMOs), a disorder that is inherited in an autosomal dominant manner.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / radiography. Osteochondroma / pathology. Osteochondroma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853760.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.224 / exostosin-1; EC 2.4.1.224 / exostosin-2
  • [Number-of-references] 125
  •  go-up   go-down


55. Moon IS, Kim J, Lee HK, Lee WS: Surgical treatment and outcomes of temporal bone chondroblastoma. Eur Arch Otorhinolaryngol; 2008 Dec;265(12):1447-54
Genetic Alliance. consumer health - Chondroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment and outcomes of temporal bone chondroblastoma.
  • Chondroblastoma is an uncommon primary benign bone tumor that usually arises in the epiphyses of the long bones.
  • Temporal bone chondroblastoma is a rare primary bone tumor that affects the floor of the middle cranial fossa and temporomandibular joint (TMJ).
  • The biological nature of temporal bone chondroblastoma is occasionally aggressive because of local invasion and is known to have a high recurrence after curettage.
  • The authors have retrospectively analyzed four cases of temporal bone chondroblastoma that had been completely excised by a single surgeon with an eventual long-term follow-up.
  • In all cases, the tumor involved the middle cranial fossa dura and the mandibular fossa with variable degree of infiltration.
  • All patients have had no tumor recurrence to date (mean follow-up period of 5 years).
  • Complete surgical resection of the temporal bone chondroblastoma is the gold standard for treatment.
  • Precise preoperative image evaluation of tumor extension and proper management of the dura mater and temporomandibular joint (TMJ) are the major important features in complete surgical removal that minimize complications in temporal bone chondroblastoma treatment.
  • [MeSH-major] Chondroblastoma / surgery. Skull Neoplasms / surgery. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Oct;54(4):430-5 [6292808.001]
  • [Cites] Neurol India. 2002 Dec;50(4):534-6 [12577121.001]
  • [Cites] Neuroradiology. 1986;28(4):367-70 [3762919.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Sep;101(9):763-9 [1514755.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):70-1 [8427113.001]
  • [Cites] Neuropathology. 2005 Jun;25(2):159-64 [15875910.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14 (5):559-64 [10576153.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Oct;19(7):319-22 [1752973.001]
  • [Cites] J Laryngol Otol. 1994 Dec;108(12):1115-9 [7861099.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):597-8 [10912709.001]
  • [Cites] Cancer. 1972 Aug;30(2):401-13 [5051664.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Sep;121(3):327-30 [10471886.001]
  • [Cites] Am J Pathol. 1942 Nov;18(6):969-91 [19970672.001]
  • [Cites] Surg Neurol. 2005 Mar;63(3):265-8; discussion 268 [15734522.001]
  • [Cites] Cranio. 2004 Apr;22(2):160-8 [15134417.001]
  • [Cites] Surg Gynecol Obstet. 1950 May;90(5):602-12 [15418430.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Mar;102(3):264-9 [2108415.001]
  • [Cites] Am J Otolaryngol. 2003 Nov-Dec;24(6):370-3 [14608568.001]
  • (PMID = 18401591.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Cordeiro SZ, Cordeiro Pde B, Sousa AM, Lannes DC, Pierro GS: Giant cell tumor of the rib occupying the entire hemithorax. J Bras Pneumol; 2008 Mar;34(3):185-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib occupying the entire hemithorax.
  • The authors report the case of a 28-year-old female patient with a giant cell tumor originating from the rib.
  • The tumor, measuring 25 x 17 cm, occupied the entire hemithorax and caused atelectasis of the left lung.
  • This tumor was a benign mesenchymal neoplasm, which rarely affects the ribs.
  • A thoracotomy involving en bloc resection of the chest wall and tumor was performed.
  • Despite the large dimensions of the tumor, complete resection was possible, and lung function was restored.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Ribs

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392468.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


57. Fnini S, Labsaili N, Messoudi A, Largab A: [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis]. Chir Main; 2008 Feb;27(1):54-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis].
  • [Transliterated title] Tumeur à cellules géantes de la phalange proximale du pouce: résection-autogreffe iliaque et arthrodèse bipolaire.
  • Giant cell tumours (GCT) of bone are frequent, with variable behaviour, high risk of recurrence and an often benign histological appearance.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone. Thumb
  • [MeSH-minor] Arthrodesis. Biopsy. Bone Nails. Bone Transplantation. Finger Joint. Follow-Up Studies. Fracture Fixation, Internal / instrumentation. Fractures, Spontaneous / etiology. Fractures, Spontaneous / surgery. Humans. Male. Metacarpophalangeal Joint. Middle Aged. Neoplasm Staging. Patient Satisfaction. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248835.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


58. Tan GC, Shiran MS, Swaminathan M, Phang KS, Rohaizak M: Large retrosternal parathyroid carcinoma with primary hyperparathyroidism. Asian J Surg; 2007 Oct;30(4):286-9
Genetic Alliance. consumer health - Parathyroid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid carcinoma is an indolent tumour with rather low malignant potential.
  • Consideration of parathyroid carcinoma in the differential diagnosis of hypercalcaemic disorders is important because the morbidity and mortality are substantial and the best prognosis is associated with early recognition and surgical resection.
  • Clinical indicators favouring parathyroid carcinoma over benign disease include markedly raised serum calcium levels, PTH and alkaline phosphatase.
  • We report a case of parathyroid carcinoma occurring in a 55-year-old woman who presented with bone pain and hypercalcaemia.

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962134.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Lin TM, Chang HW, Wang KH, Kao AP, Chang CC, Wen CH, Lai CS, Lin SD: Isolation and identification of mesenchymal stem cells from human lipoma tissue. Biochem Biophys Res Commun; 2007 Oct 5;361(4):883-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoma is a benign neoplasm of normal fat cells that appears as a soft, movable swelling, often with a slight yellowish coloration.
  • Human mesenchymal stem cells (MSCs) that have been isolated from bone marrow, blood, and other adult tissues including adipose tissue have the potential to be useful candidates for therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679141.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Eloy P, Watelet JB, Hatert AS, de Wispelaere J, Bertrand B: Endonasal endoscopic resection of juvenile nasopharyngeal angiofibroma. Rhinology; 2007 Mar;45(1):24-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile angiofibroma (JNA) is a rare benign but locally aggressive tumour of the nasopharynx that primarily occurs in adolescent males.
  • The tumour involved the nasopharynx in all the cases (6/6), the sphenoid sinus (3/6) and the medial part of the pterygopalatine fossa (4/6).
  • Based upon the recent international literature, endonasal surgery combined with a preoperative embolization of the arterial supply is indicated for small and middle size JNAs but also for large tumours extended to the pterygopalatine fossa and medial aspect of the infratemporal fossa.
  • A tridimentional guiding system can be of some help in large tumours.
  • [MeSH-minor] Adolescent. Adult. Blood Loss, Surgical. Child. Embolization, Therapeutic. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / pathology. Nose Neoplasms / surgery. Palate / surgery. Paranasal Sinus Neoplasms / surgery. Reoperation. Skull Base Neoplasms / surgery. Sphenoid Bone / surgery. Sphenoid Sinus / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432065.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


61. Durand S, Hamcha H, Pannier S, Padovani JP, Finidori G, Glorion C: [Fibrous dysplasia of the proximal femur in children and teenagers: surgical results in 22 cases]. Rev Chir Orthop Reparatrice Appar Mot; 2007 Feb;93(1):17-22
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La dysplasie fibreuse de l'extrémité proximale du fémur chez l'enfant et l'adolescent: résultats du traitement chirurgical dans 22 cas.
  • PURPOSE OF THE STUDY: Fibrous dysplasia is a rare benign bone tumor which occurs preferentially in the proximal femur.
  • For the monostotic forms, the type of treatment depended on the size of the tumor and its localization but curettage was used in all cases.
  • Nearly total involution of the tumor was noted in 75% of patients.
  • [MeSH-major] Femur / surgery. Fibrous Dysplasia of Bone / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Density Conservation Agents / therapeutic use. Bone Nails. Child. Child, Preschool. Cohort Studies. Curettage. Diphosphonates / therapeutic use. Female. Fibrous Dysplasia, Monostotic / surgery. Fibrous Dysplasia, Polyostotic / surgery. Humans. Internal Fixators. Male. Osteotomy / instrumentation. Osteotomy / methods. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389820.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


62. Ogbureke KU, Nashed MN, Ayoub AF: Huge peripheral osteoma of the mandible: a case report and review of the literature. Pathol Res Pract; 2007;203(3):185-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteomas are rare benign tumors of bone commonly occurring in the maxillofacial skeleton.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307307.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


63. Inoue N, Izui-Sarumaru T, Murakami Y, Endo Y, Nishimura J, Kurokawa K, Kuwayama M, Shime H, Machii T, Kanakura Y, Meyers G, Wittwer C, Chen Z, Babcock W, Frei-Lahr D, Parker CJ, Kinoshita T: Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood; 2006 Dec 15;108(13):4232-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both cases, der(12) had a break within the 3' untranslated region of HMGA2, the architectural transcription factor gene deregulated in many benign mesenchymal tumors, that caused ectopic expression of HMGA2 in the bone marrow.
  • These observations suggest that aberrant HMGA2 expression, in concert with mutant PIGA, accounts for clonal hematopoiesis in these 2 patients and suggest the concept of PNH as a benign tumor of the bone marrow.
  • [MeSH-major] Biomarkers, Tumor / genetics. Hematopoiesis / genetics. Hemoglobinuria, Paroxysmal / genetics. Membrane Proteins / deficiency. Mutation. Neoplasms / genetics

  • Genetic Alliance. consumer health - Hemoglobinuria.
  • Genetic Alliance. consumer health - Paroxysmal nocturnal hemoglobinuria.
  • Genetics Home Reference. consumer health - paroxysmal nocturnal hemoglobinuria.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 May 12;275(19):14394-400 [10747931.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1308-14 [16179371.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7970-5 [11427729.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4537-41 [11494149.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1583-91 [11576996.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):63-81 [11602345.001]
  • [Cites] Cancer Invest. 2002;20(3):362-72 [12025232.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1236-42 [12393680.001]
  • [Cites] Int J Hematol. 2003 Feb;77(2):107-12 [12627844.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jun;143(2):160-8 [12781451.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9104-16 [14645522.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] J Immunol. 1988 Dec 15;141(12):4283-90 [2461988.001]
  • [Cites] Baillieres Clin Haematol. 1989 Jan;2(1):113-38 [2645958.001]
  • [Cites] Science. 1993 Feb 26;259(5099):1318-20 [7680492.001]
  • [Cites] Cell. 1993 May 21;73(4):703-11 [8500164.001]
  • [Cites] Trends Genet. 1994 Mar;10(3):94-100 [8178371.001]
  • [Cites] N Engl J Med. 1995 Nov 9;333(19):1253-8 [7566002.001]
  • [Cites] Blood. 1996 May 1;87(9):3600-6 [8611683.001]
  • [Cites] Am J Hematol. 1996 Mar;51(3):229-33 [8619404.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4793-7 [10519386.001]
  • [Cites] Blood. 2005 May 15;105(10):3848-54 [15687243.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3699-709 [16051736.001]
  • [Cites] J Clin Invest. 2000 Sep;106(5):637-41 [10974016.001]
  • (PMID = 16940417.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR020043
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / phosphatidylinositol glycan-class A protein
  • [Other-IDs] NLM/ PMC1895453
  •  go-up   go-down


64. Mayilvahanan N, Paraskumar M, Sivaseelam A, Natarajan S: Custom mega-prosthetic replacement for proximal humeral tumours. Int Orthop; 2006 Jun;30(3):158-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Custom mega-prosthetic replacement for proximal humeral tumours.
  • We used custom mega-prostheses in 57 patients with aggressive benign and malignant tumours of the proximal humerus.
  • The most common tumour was osteosarcoma, followed by giant cell tumour and chondrosarcoma.
  • We achieved extra-articular and wide resection margins in all primary malignant tumours and narrow margins in benign and metastatic tumours.
  • [MeSH-major] Bone Neoplasms / therapy. Bone Substitutes. Humerus / pathology. Prosthesis Design
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Osteosarcoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2000 Jun;126(6):337-44 [10870644.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):808-13 [10530841.001]
  • [Cites] J Bone Joint Surg Am. 2000 Nov;82-A(11):1594-602 [11097450.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):156-76 [11953608.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Jun;88(4):373-8 [12124537.001]
  • [Cites] J Bone Joint Surg Br. 2002 Sep;84(7):1004-8 [12358362.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Orthopedics. 1985 May;8(5):612-21 [3912743.001]
  • [Cites] Clin Orthop Relat Res. 1987 Nov;(224):178-91 [3665239.001]
  • [Cites] J Bone Joint Surg Am. 1988 Mar;70(3):369-76 [3279038.001]
  • [Cites] J Bone Joint Surg Am. 1990 Mar;72(3):334-45 [2135632.001]
  • [Cites] Ann Chir Gynaecol. 1990;79(3):157-60 [2264717.001]
  • [Cites] Clin Orthop Relat Res. 1995 Feb;(311):164-75 [7634572.001]
  • [Cites] J Bone Joint Surg Am. 1995 Aug;77(8):1154-65 [7642659.001]
  • [Cites] J Bone Joint Surg Am. 1995 Nov;77(11):1742-54 [7593087.001]
  • [Cites] J Bone Joint Surg Am. 1996 Dec;78(12):1872-88 [8986665.001]
  • [Cites] Clin Orthop Relat Res. 1999 Mar;(360):207-20 [10101327.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):660-71 [10360694.001]
  • [Cites] J Bone Joint Surg Am. 1999 Aug;81(8):1138-46 [10466646.001]
  • [Cites] Yonsei Med J. 2000 Jun;41(3):304-11 [10957883.001]
  • (PMID = 16565840.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Substitutes
  • [Other-IDs] NLM/ PMC2532098
  •  go-up   go-down


65. Cansiz H, Güvenç MG, Sekercioğlu N: Surgical approaches to juvenile nasopharyngeal angiofibroma. J Craniomaxillofac Surg; 2006 Jan;34(1):3-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Juvenile nasopharyngeal angiofibromas are highly vascular, non-encapsulated tumours affecting predominantly young males.
  • These lesions are benign histologically but they may become life-threatening with excessive bleeding or intracranial extension.
  • Three stage I tumours, 8 stage II tumours, 6 stage III tumours and 5 stage IV tumours were included into this study.
  • The complications encountered in the postoperative course include temporary facial palsy in one patient (following a Fisch C infratemporal resection), mild crusting in the nasal cavity in 8 patients, and facial paraesthesia in 6 patients whose tumours were resected via midfacial degloving, and rupture of the subpetrous part of the internal carotid artery in one patient.
  • [MeSH-minor] Adolescent. Adult. Carotid Artery Injuries / etiology. Carotid Artery, Internal / pathology. Child. Craniotomy / adverse effects. Endoscopy. Facial Paralysis / etiology. Frontal Bone / surgery. Humans. Male. Neoplasm Staging. Nose / surgery. Nose Diseases / etiology. Paresthesia / etiology. Postoperative Complications. Retrospective Studies. Rupture. Temporal Bone / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343920.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


66. Röpke M, Boltze C, Meyer B, Neumann HW, Roessner A, Schneider-Stock R: Rb-loss is associated with high malignancy in chondrosarcoma. Oncol Rep; 2006 Jan;15(1):89-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the loss of heterozygosity (LOH) of the Rb gene in 31 formalin-fixed, paraffin-embedded cartilaginous tumors using polymerase chain reaction.
  • The tumors were subdivided into 8 cases of dedifferentiated (DD) chondrosarcoma, 17 cases of conventional chondrosarcoma (nine grade 1, seven grade 2 and one grade 3), 4 enchondromas and 2 chondroblastomas.
  • All tumors with Rb-LOH were immunohistochemically Rb-negative.
  • The only case of DD chondrosarcoma negative for Rb-LOH in both components of the tumor also showed weak expression of the Rb protein in the anaplastic component.
  • All benign cartilaginous tumors, low-grade chondrosarcomas and low-grade tumor components of DD chondrosarcomas were negative regarding Rb-LOH but positive in Rb immunohistostaining.
  • However, it is not a marker for identifying low-grade tumors with a tendency towards progression or local recurrence.
  • [MeSH-major] Bone Neoplasms / diagnosis. Chondrosarcoma / diagnosis. Genes, Retinoblastoma / genetics. Loss of Heterozygosity / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA, Neoplasm / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retinoblastoma Protein / analysis. Retinoblastoma Protein / genetics

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328039.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Retinoblastoma Protein
  •  go-up   go-down


67. Johann AC, de Freitas JB, de Aguiar MC, de Araújo NS, Mesquita RA: Peripheral osteoma of the mandible: case report and review of the literature. J Craniomaxillofac Surg; 2005 Aug;33(4):276-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteoma is a benign often asymptomatic neoplasm, consisting of well-differentiated mature bone.
  • CONCLUSION: The peripheral type of osteoma is most common in the lower jaws, occurs at the surface of the cortical bone and is sessile or pedicled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979316.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Number-of-references] 59
  •  go-up   go-down


68. Wanyura H, Kamiński A, Stopa Z: Treatment of osteomas located between the anterior cranial base and the face. J Craniomaxillofac Surg; 2005 Aug;33(4):267-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Osteomas located on the border between the anterior cranial base and the facial region are benign, often asymptomatic and usually slow growing.
  • In all patients a radical surgical removal of the tumour was performed via bifrontal craniotomy, with an extradural approach to the anterior cranial fossa.
  • The resulting defects were repaired with autologous bone grafts.
  • [MeSH-minor] Adult. Blepharoptosis / etiology. Diplopia / etiology. Female. Headache / etiology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Orbital Neoplasms / surgery. Retreatment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975808.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


69. Keser S, Bayar A: Osteochondroma of the talar neck: a rare cause of callosity of the foot dorsum. J Am Podiatr Med Assoc; 2005 May-Jun;95(3):295-7
MedlinePlus Health Information. consumer health - Corns and Calluses.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common benign bone tumor.
  • [MeSH-major] Bone Neoplasms / complications. Callosities / etiology. Osteochondroma / complications. Talus

  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901820.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Simsek A, Sipahioğlu S, Ataoğlu O, Cila E: Clear cell chondrosarcoma of the proximal femur with intrapelvic extension. Arch Orthop Trauma Surg; 2005 Feb;125(1):66-9
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell chondrosarcoma is a rare tumor that can be easily confused with benign tumors.
  • The aim of this report is to present a case that is rare, initially diagnosed as aneurysmal bone cyst and then chondroblastoma, and has an interesting extension pattern.
  • A 41-year-old male patient was treated for an apparently benign cystic lesion of the right proximal femur by intralesional excision and bone grafting.
  • The pathological diagnosis was aneurysmal bone cyst.
  • Both tumors were resected with a wide margin on the femoral side and a marginal margin on the intrapelvic side.
  • Again, the pathological diagnosis was chondroblastoma.
  • Clinically and pathologically, clear cell chondrosarcoma may be confused with benign bone tumors.
  • This caused a delay in the final diagnosis of this patient and he received inadequate surgical treatment, leading to a hemipelvectomy.
  • We were unable to find an exact explanation for this finding and postulated that tumor cells might have been seeded into the inner wall of the acetabulum during acetabular preparation of the total hip prosthesis.
  • [MeSH-major] Chondrosarcoma / diagnosis. Femoral Neoplasms / diagnosis. Pelvic Neoplasms / secondary. Sarcoma, Clear Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558292.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Jordan E, Choe D, Miller T, Chamarthy M, Brook A, Freeman LM: Utility of bone scintigraphy to determine the appropriate vertebral augmentation levels. Clin Nucl Med; 2010 Sep;35(9):687-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of bone scintigraphy to determine the appropriate vertebral augmentation levels.
  • However, diagnosis and localization of the causative vertebral level(s) may be difficult using any single imaging modality.
  • In this retrospective study, we assessed the ability of preprocedural bone scans to determine the appropriate level(s) of subsequent vertebroplasty.
  • MATERIALS AND METHODS: The study consisted of a retrospective chart review of 44 patients who underwent bone scintigraphs and vertebroplasties at Montefiore Medical Center from 2002 to 2008.
  • Online medical records and reports were used to determine the level of vertebroplasty and the preprocedure bone scan levels.
  • RESULTS AND CONCLUSIONS: Our retrospective study assessed the utility of bone scans as a diagnostic tool to identify candidate vertebral levels for vertebroplasty and determined that bone scans were positive in 78.3% of all fractures that subsequently underwent vertebral augmentation procedures.
  • Although no significant difference was seen in the positivity of bone scans to subsequent vertebroplasty levels between benign or metastatic compression fractures (79% vs. 76%), a difference was observed when single level vertebroplasty patients were compared with multiple-level vertebroplasty patients (87% vs. 69%).
  • Our results support the use of whole body bone scintigraphy as a diagnostic tool prior to vertebroplasty, especially in cases where a single vertebral level is involved or MRI might be contraindicated.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Neoplasm Metastasis. Osteoporosis / radionuclide imaging. Osteoporosis / surgery. Spinal Fractures / radionuclide imaging. Spinal Fractures / surgery. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / surgery. Whole-Body Irradiation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706042.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Bikmaz K, Mrak R, Al-Mefty O: Management of bone-invasive, hyperostotic sphenoid wing meningiomas. J Neurosurg; 2007 Nov;107(5):905-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of bone-invasive, hyperostotic sphenoid wing meningiomas.
  • OBJECT: The hyperostosis frequently associated with sphenoid wing meningiomas is actual invasion of bone by the tumor.
  • The intracranial portion of the tumor is usually thin with en plaque spread, and the tumor tends to invade the orbit through the superior orbital fissure.
  • Seventeen of the patients had the distinguishing characteristics of hyperostotic sphenoid wing meningiomas-extensive bone invasion, en plaque dural involvement, and a minimal intracranial mass with minimal orbital involvement.
  • Histopathological evaluation of bone specimens was performed in 14 cases.
  • Chromosome analysis was performed in all tumors resected since 2001 (seven cases).
  • Particular attention was paid to removing all involved bone and dura mater.
  • CONCLUSIONS: Sphenoid wing meningiomas frequently invade bone, although such invasion does not represent malignancy.
  • These lesions are generally histologically benign.
  • This requires extensive drilling of the invaded bone and extensive excision of the involved dura.
  • Extensive bone resection should be followed by cranioorbital reconstruction for good cosmesis and to prevent enophthalmos.
  • [MeSH-major] Hyperostosis / pathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Invasiveness / pathology. Orbit / pathology
  • [MeSH-minor] Adult. Aged. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977259.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


73. Matsuo T, Hiyama E, Sugita T, Shimose S, Kubo T, Mochizuki Y, Adachi N, Kojima K, Sharman P, Ochi M: Telomerase activity in giant cell tumors of bone. Ann Surg Oncol; 2007 Oct;14(10):2896-902
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in giant cell tumors of bone.
  • BACKGROUND: A giant cell tumor of bone (GCT) is a histologically benign neoplasma that has an unpredictable pattern of biological aggressiveness.
  • The telomere lengths of tumors were significantly shorter than those of normal tissue (P = .008).
  • The mean telomere length of grade 3 tumors was significantly shorter than those of grade 1 and 2 tumors (P = .038).
  • Telomerase activity was detected in 81% of tumor samples.
  • The level of telomerase activity in tumors with local recurrence was significantly higher than in tumors without local recurrence (P = .011).
  • [MeSH-major] Bone Neoplasms / genetics. Giant Cell Tumor of Bone / genetics. Telomerase / genetics
  • [MeSH-minor] Adolescent. Adult. Blotting, Southern. Bone and Bones / pathology. Bone and Bones / surgery. Extremities / surgery. Female. Femoral Neoplasms / genetics. Femoral Neoplasms / pathology. Femoral Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length / genetics. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653593.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


74. Sampol Bas C, Peña Viloria C, Giménez García M: [Solitary hypermetabolic bone focus in the initial extension study of a prostate carcinoma]. Rev Esp Med Nucl; 2005 Nov-Dec;24(6):414-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary hypermetabolic bone focus in the initial extension study of a prostate carcinoma].
  • [Transliterated title] Foco óseo hipermetabólico único en el estudio de extensión inicial de un carcinoma de próstata.
  • 56 year old male who was diagnosed of Prostatic Neoplasm by transrectal biopsy after elevated PSA level was found by chance in a routine control.
  • This was followed by a whole body bone scintigraphy with 99mTc-MDP that showed a solitary hypermetabolic lesion within skull.
  • An MRI and a CT head scan were carried out to characterize the isotopic lesion, finding no bone abnormalities to justify the mentioned uptake.
  • Given the absence of a radiological benign diagnosis, a further FDG-PET scan was carried out which did not show either increased glycolytic activity at the left occipital region, or in the prostatic gland.
  • In order to guide the biopsy, a CT head scan was repeated which showed what appeared to be an incipient blastic lesion in the scale of the left occipital bone, establishing the differential diagnosis between a metastasis and a benign process.
  • The anatomopathologic analysis of the bone tissue describes a necrotic process without inflammatory reaction (osteonecrosis).
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Occipital Bone / radionuclide imaging. Osteonecrosis / radionuclide imaging. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Biomarkers, Tumor / blood. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Diagnosis, Differential. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Proteins / blood. Positron-Emission Tomography. Prostate-Specific Antigen / blood. Radiopharmaceuticals / pharmacokinetics. Skull Neoplasms / radionuclide imaging. Skull Neoplasms / secondary. Technetium Tc 99m Medronate / pharmacokinetics. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324519.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; EC 3.4.21.77 / Prostate-Specific Antigen; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


75. Lanza A, Laino L, Rossiello L, Perillo L, Ermo AD, Cirillo N: Clinical Practice: Giant Cell Tumour of the Jaw Mimicking Bone Malignancy on Three-Dimensional Computed Tomography (3D CT) Reconstruction. Open Dent J; 2008;2:73-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Practice: Giant Cell Tumour of the Jaw Mimicking Bone Malignancy on Three-Dimensional Computed Tomography (3D CT) Reconstruction.
  • Periapical inflammation, cysts and benign tumours, bone malignancies, all of these conditions may show bone resorption on radiograph.
  • Features of the surrounding bone, margins of the lesion, and biological behaviour including tendency to infiltration and root resorption, may represent important criteria for distinguishing benign tumours from their malign counterpart, although the radiographic aspect of the lesion is not always predictive.
  • Therefore a critical differential diagnosis has to be reached to choose the best management.
  • Here, we report a case of giant cell tumour (GCT) whose radiological features by computed tomography (CT) suggested the presence of bone malignancy, whereas the evaluation of a routine OPT scan comforted us about the benign nature of the lesion.
  • A brief review of the literature on such a benign but locally aggressive neoplasm is also provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Feb;24(1):26-9 [15270430.001]
  • [Cites] J Oral Pathol Med. 1989 Mar;18(3):128-32 [2503607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):158-65 [12909228.001]
  • [Cites] J Craniofac Surg. 2003 Mar;14(2):201-6; discussion 207-8 [12621291.001]
  • [Cites] Oral Oncol. 2002 Apr;38(3):219-26 [11978543.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):331-41 [11904346.001]
  • [Cites] Minerva Stomatol. 1999 Nov;48(11):553-8 [10768015.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):361-6 [17388930.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2007 Sep;12(5):E401-3 [17767108.001]
  • [Cites] Cytopathology. 2007 Jun;18(3):184-90 [17573765.001]
  • [Cites] Diagn Cytopathol. 2007 Jun;35(6):358-62 [17497658.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1142-3; discussion E1143 [17143206.001]
  • [Cites] Singapore Med J. 2006 Aug;47(8):679-83 [16865207.001]
  • [Cites] Oral Dis. 2007 Jan;13(1):82-7 [17241435.001]
  • [Cites] Ear Nose Throat J. 2005 Jul;84(7):432-4 [16813033.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):589-94 [16465417.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jul;63(7):989-95 [16003628.001]
  • [Cites] J Egypt Natl Canc Inst. 2004 Sep;16(3):145-52 [15959547.001]
  • [Cites] Oral Oncol. 2005 May;41(5):480-8 [15878752.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Mar;63(3):311-8 [15742279.001]
  • [Cites] Am J Otolaryngol. 1996 Nov-Dec;17(6):407-10 [8944301.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 2;65(2):143-6 [12176185.001]
  • (PMID = 19088886.001).
  • [ISSN] 1874-2106
  • [Journal-full-title] The open dentistry journal
  • [ISO-abbreviation] Open Dent J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2581533
  •  go-up   go-down


76. Liedauer R, Svoboda M, Wlcek K, Arrich F, Jä W, Toma C, Thalhammer T: Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep; 2009 Dec;22(6):1485-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts.
  • OATP expression had been shown in different tissues, but not in bone tumors.
  • Therefore, the expression pattern of all known eleven human OATPs was analyzed by quantitative RT-PCR in 21 human bone tumor specimens (osteosarcomas, bone metastases and benign aneurysmal bone cysts).
  • Transcriptional expression of OATP1A2, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1 and 5A1, but not of OATP1B1, 1B3 and 6A1 was observed in malignant and non-malignant tumor specimens at varying level.
  • Importantly, OATP3A1, 4A1, 2B1 and 1C1 mRNA levels were significantly higher in aneurysmal bone cysts as compared to osteosarcomas.
  • Elevated mRNA levels of OATP2A1, 1A2, and 4C1 in metastases from kidney cancer and of OATP5A1 in prostate cancer suggest that the OATP expression pattern in metastases is comparable to that of the primary tumors.
  • Different to tissue, OATP expression in osteosarcoma cell lines HOS and MG-63, normal human osteoblast outgrowth cells (hOB) and bone marrow stromal cells (BMSC) is limited to OATP3A1 and OATP4A1.
  • High OATP expression levels, particularly in benign bone tumors, suggest an important role of these transporters for providing hormones, their conjugates, prostaglandins and drugs in bone cells.
  • Thereby, they may influence bone resorption and formation.
  • [MeSH-major] Bone Cysts, Aneurysmal / metabolism. Bone Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Organic Anion Transporters / metabolism. Osteosarcoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Resorption. Cell Line, Tumor. Child. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Neoplasm Metastasis. Transcription, Genetic

  • Genetic Alliance. consumer health - Aneurysmal Bone Cysts.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885603.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organic Anion Transporters
  •  go-up   go-down


77. Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J: Cryosurgery in aggressive, benign, and low-grade malignant bone tumours. Lancet Oncol; 2005 Jan;6(1):25-34
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryosurgery in aggressive, benign, and low-grade malignant bone tumours.
  • Cryosurgery is a method of treatment for various tumours that induces tissue necrosis with ablative intent.
  • It is used in benign, aggressive, and low-grade malignant bone tumours such as chondrosarcoma grade 1.
  • At the University Medical Centre Nijmegen, Netherlands, 302 tumours have been treated by use of cryosurgery with at least 2 years' follow-up.
  • 96-100% of patients were cured-the response depended on tumour type.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. Cryosurgery / methods
  • [MeSH-minor] Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629273.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


78. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer; 2010;10:483
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.
  • METHODS: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
  • The VDR was frequently expressed in benign lesions (93.5%) and its levels of expression were diminished in invasive tumours (56.2%).
  • CYP27B1 expression is slightly lower in invasive carcinomas (44.6%) than in benign lesions (55.8%).
  • In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
  • CONCLUSIONS: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic pathways in breast cancer, favouring tumour progression.
  • Thus, during mammary malignant transformation, tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D effects, while increasing their ability to degrade this hormone.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cohort Studies. Disease Progression. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Metabolic Networks and Pathways. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Vitamin D3 24-Hydroxylase

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 1994 May;12(3):195-202 [8194194.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):239-44 [1846309.001]
  • [Cites] J Histochem Cytochem. 1998 Nov;46(11):1335-7 [9774633.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1721S-4S [15585794.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28 [15951480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2370-6 [16214919.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):688-94 [16012853.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):153-64 [16111884.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R980-6 [16280049.001]
  • [Cites] Science. 2006 Apr 14;312(5771):233-6 [16614213.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92 [16828283.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Virchows Arch. 2007 Jan;450(1):73-80 [17123107.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Proc Nutr Soc. 2008 May;67(2):115-27 [18412986.001]
  • [Cites] J Cell Biochem. 2008 Nov 1;105(4):980-8 [18767073.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):155-7 [19331145.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1328-33 [19437538.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):702-9 [19570947.001]
  • [Cites] J Cell Biochem. 1999 Dec 15;75(4):640-51 [10572247.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):144-6 [10835626.001]
  • [Cites] Circ Res. 2000 Aug 4;87(3):214-20 [10926872.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3371-9 [10955825.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Histochem J. 2002 Jan-Feb;34(1-2):35-40 [12365798.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):67-80 [12644300.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6793-9 [2824042.001]
  • [Cites] Science. 1988 May 13;240(4854):889-95 [3283939.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):607-13 [2842365.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):233-9 [2458030.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • (PMID = 20831823.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2945944
  •  go-up   go-down


79. Bostan B, Sen C, Gunes T, Erdem M, Koseoglu RD: Osteoid osteoma of the trapezium: case report. J Hand Surg Am; 2010 Apr;35(4):636-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma is a benign bone tumor representing approximately 10% of all benign bone tumors.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteoma, Osteoid / diagnosis. Trapezium Bone / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20171814.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Domovitov SV, Healey JH: Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol; 2010 Mar;17(3):694-701
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant giant-cell tumor of bone has high survival rate.
  • BACKGROUND: Malignant giant-cell tumors (MGCT) comprise 2-9% of all giant-cell tumors (GCTs).
  • This study compared malignant to benign GCTs and defined the clinical outcome of the patients in a large series of case-matched patients from a single institution.
  • METHODS: Clinical, radiological, and outcome features were compared between 26 malignant and 244 benign GCTs treated in our institution.
  • We also performed a 1:2 case-matched comparison of patients with malignant and benign disease.
  • Campanacci stage 1 tumors had a low probability of malignancy (P = 0.017).
  • MGCT were less likely to have aneurysmal bone cyst changes.
  • The 5-year recurrence-free status probability was 80% for malignant and 91% for benign cases in matched groups.
  • The difference in the recurrence rate between benign and malignant groups was not statistically significant (P = 0.24).
  • Functional impairment and limited activity were greater in MGCT patients than in benign GCT patients, whether treated by resection/amputation or curettage/cryosurgery.
  • CONCLUSIONS: We found that malignant and benign GCT have similar epidemiology and that recurrence was higher in MGCT (20 v 9%).
  • [MeSH-major] Bone Neoplasms / mortality. Giant Cell Tumor of Bone / mortality. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902306.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


81. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • 145 had histologically confirmed BC (92 with bone metastases), 20 UBC (6 with bone metastases), 11 LC (3 with bone metastases) and 129 PC (68 with bone metastases).
  • In BC patients we compared the PICP and ICTP levels with those of CA 15-3, CEA and bone scintigraphy.
  • Patients with LC and UBC had PICP and ICTP measurements, PC patients had serum PICP, prostate specific antigen (PSA) measurements and bone scans.
  • RESULTS: ICTP and CA 15-3 levels were significantly higher in patients with BC and bone metastases in comparison to patients without metastases (p <0.05), while PICP and CEA were only marginally higher.
  • Significant correlation was observed between existence of bone metastases and ICTP levels (p <0.05).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • In LC patients, ICTP levels differed significantly between patients with and without bone metastases (p=0.025).
  • In UBC patients, PICP levels differed significantly between patients with and without bone metastases (p=0.017).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • PICP could be useful for diagnosing early bone metastases of PC and combined with PSA and bone scan can be an additional tool in the follow-up of PC patients.
  • For LC patients, ICTP showed a significant difference in the discrimination of patients with and without bone metastases.
  • In UBC patients, PICP showed a significant difference in the discrimination of patients with and without bone metastases.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


82. Matsubayashi S, Nakashima M, Kumagai K, Egashira M, Naruke Y, Kondo H, Hayashi T, Shindo H: Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract; 2009;205(9):626-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
  • Giant cell tumor of bone (GCTB) is a benign neoplasm but occasionally shows local recurrence, and histologically consists of osteoclast-like giant cells (GC) and stromal mononuclear cells (SC), which are capable of proliferation and osteoblastic differentiation.
  • Activation of Wnt signaling can induce osteoblast differentiation and osteoclastgenesis during bone resorption process.
  • We performed immunohistochemistry for beta-catenin, cyclin D1, and Ki-67 in 16 GCTB tumors, including 5 recurrent cases that were surgically resected.
  • The nuclear beta-catenin labeling index (LI) in both SC (60.6 vs. 41.8%, p=0.074) and GC (41.7 vs. 20.1%, p=0.095) was higher in recurrent tumors than in primary tumors in all the 4 cases.
  • However, Ki-67 LI in SC (18.8 vs. 19.9%, p=0.851) and cyclin D1 LI in GC (55.4 vs. 70.1%, p=0.225) were not higher in recurrent tumors than in primary tumors.
  • Importantly, it was suggested that the nuclear beta-catenin staining level might be associated with tumor recurrence in GCTB.
  • [MeSH-major] Bone Neoplasms / metabolism. Cyclin D1 / biosynthesis. Giant Cell Tumor of Bone / metabolism. Wnt Proteins / metabolism. beta Catenin / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Cell Nucleus / metabolism. Female. Gene Expression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Signal Transduction / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324500.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Wnt Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


83. Baena-Ocampo Ldel C, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R: Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol; 2009 Feb;13(1):16-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution.
  • A retrospective analysis of all bone tumors accessioned at a large referral center (Instituto Nacional de Rehabilitacion) in Mexico City between 2000 and 2005 is presented.
  • A total of 6216 biopsies and surgical resection specimens were reviewed during this period, of which 566 corresponded to bone tumors.
  • Benign bone tumors accounted for 71.6% of cases and malignant bone tumors for 28.4%.
  • The tumors affected men in 53.7% of cases and women in 46.3% of cases, with an average age at presentation of 25 years.
  • The femur was the most common location of the tumors (39.9%), followed by the tibia (17.7%) and humerus (11.8%).
  • The commonest malignant bone tumors were osteosarcoma (46.6%) and chondrosarcoma (8.7%).
  • Of malignant bone tumors, 18.6% corresponded to metastases of carcinomas from internal organs and 8.1% were multiple myeloma.
  • The most common benign bone tumor was osteochondroma (43.7%) followed by giant cell tumor of bone (14.6%) and enchondroma (10.1%).
  • The age distribution showed a peak in children and adolescents comprised predominantly of benign lesions and a second peak in young adults that corresponded to malignant bone tumors (principally osteosarcoma).
  • Malignant bone tumors most often involved the femur, vertebra, and tibia.
  • Geographic location does not appear to represent a risk factor for any particular type of bone tumor and does not affect the age distribution, location, or histopathologic type of the lesions.
  • [MeSH-major] Bone Neoplasms / epidemiology. Bone Neoplasms / pathology. Chondrosarcoma / epidemiology. Chondrosarcoma / pathology. Osteosarcoma / epidemiology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Chondroma / epidemiology. Chondroma / pathology. Female. Giant Cell Tumors / epidemiology. Giant Cell Tumors / pathology. Giant Cell Tumors / secondary. Humans. Incidence. Infant. Male. Mexico / epidemiology. Middle Aged. Osteochondroma / epidemiology. Osteochondroma / pathology. Referral and Consultation. Retrospective Studies. Risk Factors. Urban Population

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118777.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Bonekamp D, Jacene H, Bartelt D, Aygun N: Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med; 2008 Dec;33(12):909-11
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia (FD) accounts for 7% of benign bone tumors.
  • It is a developmental disorder of unclear etiology.
  • The lamellar cancellous bone of the medullary cavity is replaced with immature fibroosseous tissue.
  • We describe a case of FD of the skull in a patient of advanced age (69 years) with recent diagnosis of colon cancer, which changed its FDG activity and CT appearance within 10 months of follow-up.
  • [MeSH-major] Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Molecular Mimicry. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Skull / pathology. Skull / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033807.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Wang GY, Li Y, Yu YM, Yu B, Zhang ZY, Liu Y, Wang SJ: Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting. J Gastroenterol Hepatol; 2009 Feb;24(2):299-306
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting.
  • BACKGROUND AND AIM: Magnetic activated cell sorting (MACS) and fluorescent activated cell sorting (FACS) were employed to enrich and detect the gastric cancer cells from a cell line in a model system, and to enrich and detect disseminated tumor cells (DTCs) from bone marrow (BM) of patients with gastric cancer.
  • METHODS: Fifteen patients with benign gastric lesions and 35 patients with gastric cancer who received curative operations between December 2002 and June 2003 were selected.
  • Cells from cell line OCUM-2M were seeded with 10-grade ratio into mononuclear cells from patients with benign gastric lesion.
  • RESULTS: Disseminated tumor cells were detected in the BM of 25 (71.43%) patients with gastric cancer.
  • Disseminated tumor cells in BM had close correlation with tumor tumor-node-metastasis (TNM) stage (P = 0.034) and cancer-free survival (P = 0.035).
  • CONCLUSION: Disseminated tumor cells are very common in the BM of gastric cancer patients.
  • [MeSH-major] Bone Marrow Cells / pathology. Cell Separation / methods. Flow Cytometry. Immunomagnetic Separation. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD45 / analysis. Cell Differentiation. Cell Line, Tumor. Female. Gastrectomy. Humans. Kaplan-Meier Estimate. Keratin-7 / analysis. Keratin-8 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032456.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / KRT8 protein, human; 0 / Keratin-7; 0 / Keratin-8; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


86. Murata H, Horie N, Matsui T, Akai T, Ueda H, Oshima Y, Konishi E, Kubo T: Clinical usefulness of thallium-201 scintigraphy and magnetic resonance imaging in the diagnosis of chondromyxoid fibroma. Ann Nucl Med; 2008 Apr;22(3):221-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of thallium-201 scintigraphy and magnetic resonance imaging in the diagnosis of chondromyxoid fibroma.
  • Chondromyxoid fibroma (CMF) is a benign bone tumor.
  • However, it is sometimes difficult to distinguish this tumor from chondrosarcoma.
  • The tumor was diagnosed as CMF by open biopsy.
  • It is important that CMF is correctly distinguished from other tumors because this may be histologically overdiagnosed as chondrosarcoma.
  • Contrast-enhanced MR imaging and thallium-201 scintigraphy may be useful to distinguish CMF from benign bone tumors or chondrosarcoma.
  • [MeSH-minor] Adolescent. Biopsy. Citrates / pharmacokinetics. Contrast Media / pharmacokinetics. Diagnosis, Differential. Diphosphonates / pharmacokinetics. Fibroma / radiography. Fibroma / radionuclide imaging. Fibula / pathology. Gadolinium DTPA / pharmacokinetics. Gallium / pharmacokinetics. Humans. Knee Joint / pathology. Knee Joint / radiography. Knee Joint / radionuclide imaging. Knee Joint / surgery. Magnetic Resonance Imaging. Male. Osteolysis / radiography. Radionuclide Imaging. Radiopharmaceuticals / pharmacokinetics. Technetium Compounds / pharmacokinetics

  • Hazardous Substances Data Bank. GALLIUM .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498038.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Citrates; 0 / Contrast Media; 0 / Diphosphonates; 0 / Radiopharmaceuticals; 0 / Technetium Compounds; 0 / Thallium Radioisotopes; 27905-02-8 / gallium citrate; 8V3FGC4J77 / technetium Tc 99m diphosphonate; CH46OC8YV4 / Gallium; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


87. Horvai AE, Kramer MJ, Garcia JJ, O'Donnell RJ: Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol; 2008 Apr;21(4):423-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone.
  • Giant-cell tumor of bone is considered a benign, locally aggressive and rarely metastasizing neoplasm of bone.
  • However, recent evidence suggests that activity of the telomerase enzyme complex correlates with recurrence in giant-cell tumor, although the subset of cells with telomerase activity in these heterogeneous tumors has not been defined.
  • In the present study, we investigated whether immunostaining for human telomerase reverse transcriptase, a component of the telomerase complex, correlates with outcome in giant-cell tumor and the distribution of telomerase reverse transcriptase staining in these tumors.
  • We analyzed 58 cases of giant-cell tumor for the presence and pattern of telomerase reverse transcriptase immunostaining, presence of soft tissue involvement and the type of initial surgery, and correlated these findings with recurrence-free survival and metastasis-free survival.
  • Specific staining with telomerase reverse transcriptase was present in 20 out of 58 tumors (35%) in the nuclei of mononuclear cells and, occasionally, osteoclast-like giant cells.
  • Therefore, telomerase reverse transcriptase expression may predict recurrence in giant-cell tumor insofar as positive immunostaining correlates with shorter recurrence-free survival and may be a useful prognostic marker to stratify patients to more aggressive treatment protocols.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / enzymology. Giant Cell Tumor of Bone / enzymology. Telomerase / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204433.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


88. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone; 2008 Jan;42(1):68-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study.
  • BACKGROUND: Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor that is characterized by the presence of mononuclear stromal cells and multinucleated giant cells.
  • Although topical adjuvants have been used in the past, local recurrence following intralesional excision of GCT of bone continues to remain a problem.
  • The use of bisphosphonates as an anti-osteoclastic agent in the management of osteolytic bone metastases is well accepted.
  • Therefore our clinical study aims to investigate whether the administration of bisphosphonate as an adjuvant can further decrease local recurrence following the surgical treatment of GCT of bone.
  • CONCLUSION: Clinical use of bisphosphonates as an adjuvant therapy for giant cell tumor of bone demonstrated a lower local recurrence rate.
  • [MeSH-major] Bone Neoplasms. Diphosphonates / pharmacology. Extremities / pathology. Giant Cell Tumor of Bone. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962092.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


89. Naka N, Joyama S, Tsukamoto Y, Yoshioka K, Hashimoto N, Ujiiye T, Hayashi T, Kawase M, Mano M, Ishiguro S, Myoui A, Ueda T, Yoshikawa H, Araki N, Itoh K: Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn; 2005 May;7(2):187-97
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.
  • We have developed a competitive nucleic acid sequence-based amplification (NASBA) assay to analyze SSX mRNA expression in 211 bone and soft tissue tumors.
  • The copy numbers of SSX mRNA per mug of total RNA in tumor tissues were widely distributed, ranging logarithmically from 0.6 to 6.6.
  • We found that malignant tumors showed significantly higher expression of SSX mRNA than benign tumors (P < 0.0001).
  • Further, SSX mRNA expression in stage III tumors was significantly higher than that in stage I or II tumors (P < 0.005).
  • [MeSH-major] Bone Neoplasms / genetics. Neoplasm Proteins / genetics. RNA, Messenger / analysis. Repressor Proteins / genetics. Self-Sustained Sequence Replication. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. COS Cells. Child. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Neoplasm / analysis. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6223-9 [10626816.001]
  • [Cites] Nucleic Acids Res. 1998 May 1;26(9):2250-1 [9547289.001]
  • [Cites] Lett Appl Microbiol. 2000 Jan;30(1):75-9 [10728566.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1654-62 [10749136.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12198-203 [11027314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):629-34 [11149944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3282-7 [11248070.001]
  • [Cites] J Surg Res. 2001 Jun 15;98(2):76-80 [11397121.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1717-22 [11823502.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):640-2 [11920629.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):715-26 [11922625.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):448-53 [12216073.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Int J Biol Markers. 2002 Oct-Dec;17(4):219-23 [12521124.001]
  • [Cites] Cancer Immun. 2003 Oct 9;3:13 [14533943.001]
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):115-26 [15026272.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Nature. 1991 Mar 7;350(6313):91-2 [1706072.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Immunity. 1995 Feb;2(2):167-75 [7895173.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S83-8 [9578421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6919-23 [9618514.001]
  • [Cites] Int J Cancer. 1998 Jul 3;77(1):19-23 [9639388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6 [9560255.001]
  • [Cites] J Bone Joint Surg Am. 1998 Aug;80(8):1204-18 [9730132.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):2013-8 [9788446.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):664-9 [10521804.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] J Exp Med. 1995 Sep 1;182(3):689-98 [7544395.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):375-80 [7591235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4766-72 [8840996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):965-71 [9378559.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):726-32 [10699956.001]
  • (PMID = 15858142.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 164289-47-8 / synovial sarcoma X breakpoint proteins
  • [Other-IDs] NLM/ PMC1867521
  •  go-up   go-down


90. Hamama J, Choumi F, Abir B, Elkhatib K, Abouchadi A, Nassih M, Rzin A: [Pindborg's tumor: a propos of a case]. Rev Belge Med Dent (1984); 2010 Oct-Dec;65(4):159-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pindborg's tumor: a propos of a case].
  • [Transliterated title] Tumeur de Pindborg: à propos d'un cas.
  • The calcifying epithelial odontogenic tumor was first described as an entity by Danish pathologist Jens Pindborg in 1955.
  • It is an uncommon and locally invasive benign odontogenic tumor.
  • [MeSH-minor] Adult. Bone Plates. Chin / pathology. Chin / surgery. Female. Humans. Neoplasm Invasiveness. Odontogenic Tumors / pathology. Odontogenic Tumors / surgery. Reconstructive Surgical Procedures. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21384628.001).
  • [ISSN] 0775-0293
  • [Journal-full-title] Revue belge de médecine dentaire
  • [ISO-abbreviation] Rev Belge Med Dent (1984)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] Calcifying Epithelial Odontogenic Tumor
  •  go-up   go-down


91. Cueva-Del Castillo JF, Valdés-Gutiérrez GA, Elizondo-Vázquez F, Pérez-Ortiz O, Piña Barba MC, León-Mancilla BH: [Bone loss treatment, pseudoarthrosis, arthrodesis and benign tumors using xenoimplant: clinical study]. Cir Cir; 2009 Jul-Aug;77(4):287-91; 267-71
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone loss treatment, pseudoarthrosis, arthrodesis and benign tumors using xenoimplant: clinical study].
  • BACKGROUND: Bone loss as a result of arthrodesis, pseudarthrosis, benign tumors and bone defects was treated using a xenoimplant (Nukbone).
  • Twenty eight patients had arthrodesis, 16 were treated with pseudarthrosis, three patients had benign tumors and five patients presented bone defects, which were implanted with Nukbone at the site and was the correct treatment for the problem.
  • CONCLUSIONS: In Mexico, bony xenoimplants (osseous) have been used, all of foreign origin due to the high degree of technological dependence in this country.
  • In this study we describe the use, for the first time, of a Mexican xenoimplant with a patent from the Universidad Nacional Autónoma de México (UNAM).
  • The Mexican xenoimplant is biocompatible and can be adapted to treat pathologies where bony (osseous) material is needed.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Resorption / surgery. Bone Transplantation. Pseudarthrosis / surgery. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919790.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


92. Saikia KC, Bhattacharya TD, Bhuyan SK, Talukdar DJ, Saikia SP, Jitesh P: Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects. Indian J Orthop; 2008 Apr;42(2):169-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects.
  • BACKGROUND: Synthetic bio-inert materials are currently used as an alternative to autogenous bone graft.
  • The purpose of this study is to analyse the use of HA and beta-TCP in their ceramic forms as a bone graft substitute in filling bone voids after curettage of benign bone tumors.
  • MATERIALS AND METHODS: Twenty-four patients in the age range of 3.5-55 years (mean 14.3 years) having benign bone tumors with bone defects were filled with bone graft substitute following curettage.
  • In 20 patients bone defects were filled with block/granules of HA ceramic and in four with beta-TCP.
  • CONCLUSION: Calcium hydroxyapatite and beta-TCP are excellent bone graft substitutes for autogenous bone graft in filling voids after curettage of benign bone tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1989 Mar;(240):53-62 [2537166.001]
  • [Cites] J Orthop Res. 1985;3(3):301-10 [2411894.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jul;68(6):904-11 [3015975.001]
  • [Cites] J Bone Joint Surg Br. 1990 Mar;72(2):298-302 [2155908.001]
  • [Cites] J Bone Joint Surg Br. 1984 Mar;66(2):269-75 [6323483.001]
  • [Cites] Clin Orthop Relat Res. 1981 Jun;(157):259-78 [7018783.001]
  • [Cites] J Biomed Mater Res. 1975 Mar;9(2):183-95 [1100632.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jul;86(5):719-25 [15274270.001]
  • [Cites] J Bone Joint Surg Am. 2002 Mar;84-A(3):454-64 [11886919.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 2001 Jul;30(7):544-50 [11482509.001]
  • [Cites] J Bone Joint Surg Br. 2000 Nov;82(8):1117-20 [11132269.001]
  • [Cites] Injury. 2005 Nov;36 Suppl 3:S20-7 [16188545.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2005 Jan 15;72(1):94-101 [15376187.001]
  • [Cites] Orthop Clin North Am. 1999 Oct;30(4):599-613 [10471765.001]
  • [Cites] Orthop Clin North Am. 1987 Apr;18(2):323-34 [3561978.001]
  • (PMID = 19826522.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2759621
  • [Keywords] NOTNLM ; Benign bone tumor / bone graft substitute / calcium phosphate ceramic / hydroxyapatite
  •  go-up   go-down


93. Jerome JT, Sankaran B, Varghese M, Thomas S, Thirumagal SK: Rare presentation of Ewing's sarcoma: a case report and literature review. J Pediatr Orthop B; 2008 Sep;17(5):261-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical presentations represent a degree of overlap among various benign and infective etiologies.
  • The diagnosis was confirmed by gold standard biopsy.
  • We present a case of Ewing's tumor in a 13-year-old girl and discuss its rare presentation, and also offer a literature review.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / therapy. Fingers. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Amputation / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Staging. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471180.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


94. Li JM, Yang ZP, Li ZF, Li X, Carter SR: Knee reconstruction with preservation of the meniscus in tibial giant cell tumor. Clin Orthop Relat Res; 2008 Dec;466(12):3101-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knee reconstruction with preservation of the meniscus in tibial giant cell tumor.
  • Giant cell tumor of bone sometimes is an aggressive benign skeletal tumor.
  • Historically, curettage and bone grafting have a high recurrence with satisfactory function whereas wide resection has a reduced recurrence rate with compromise of limb function.
  • We developed a method for achieving both goals for giant cell tumors located in only one lateral plateau of the proximal tibia.
  • We reconstructed 13 knees preserving the meniscus and reconstructing the tibial plateau with an iliac plate autograft after resection of a giant cell tumor involving one tibial plateau.
  • Four patients had primary tumors and nine had recurrences after curettage.
  • While resecting the tumor, the normal anatomic structures of the knee can be preserved or restored in many patients.
  • This method can be used in selected patients to reconstruct the knee after resection of tumors involving one tibial plateau.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Orthopedic Procedures / methods. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adult. Bone Transplantation. Female. Humans. Ilium / transplantation. Male. Menisci, Tibial. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Tibia. Transplantation, Autologous. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] J Bone Joint Surg Br. 2004 Mar;86(2):212-6 [15046435.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):755-61 [7045129.001]
  • [Cites] Acta Orthop Scand. 1984 Apr;55(2):209-14 [6369866.001]
  • [Cites] J Bone Joint Surg Am. 1986 Feb;68(2):235-42 [3511063.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):45-58 [3514036.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1648-55 [8245057.001]
  • [Cites] J Bone Joint Surg Am. 1993 Nov;75(11):1656-62 [8245058.001]
  • [Cites] Changgeng Yi Xue Za Zhi. 1998 Mar;21(1):37-43 [9607262.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):176-88 [10078141.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):259-70 [11953617.001]
  • (PMID = 18830792.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2628220
  •  go-up   go-down


95. Hoffmann K, Kerner C, Wilfert W, Mueller M, Thiery J, Hauss J, Witzigmann H: Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol; 2007 Jan 14;13(2):257-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients.
  • AIM: To evaluate the diagnostic potential of cytokeratin-19 (CK-19) mRNA for the detection of disseminated tumor cells in blood, bone marrow and peritoneal lavage in patients with ductal adenocarcinoma of the pancreas.
  • METHODS: Sixty-eight patients with pancreatic cancer (n = 37), chronic pancreatitis (n = 16), and non-pancreatic benign surgical diseases (n = 15, control group) were included in the study.
  • Preoperative bone marrow aspirates and peritoneal lavage taken before mobilization of the tumor were analyzed.
  • All samples were evaluated for disseminated tumor cells by CK-19-specific nested-PCR and quantitative fluorogenic RT-PCR.
  • In 15 (40%) of the patients with pancreatic cancer, disseminated tumor cells were detected in venous blood and bone marrow and/or peritoneal lavage.
  • In the peritoneal lavage, the detection rates were correlated with the tumor size and the tumor differentiation.
  • CK-19 levels were increased in pT3/T4 and moderately/poorly differentiated tumors (G2/G3).
  • Pancreatic cancer patients showed significantly increased detection rates of disseminated tumor cells in blood and peritoneal lavage compared to the controls and the patients with chronic pancreatitis.
  • CONCLUSION: Disseminated tumor cells can be detected in patients with pancreatic ductal adenocarcinoma by CK-19 fluorogenic RT-PCR.
  • In peritoneal lavage, detection rate is correlated with tumor stage and differentiation.
  • In the clinical use, CK-19 is suitable for the distinction between malignant and benign pancreatic disease in combination with other tumor-specific markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / diagnosis. Keratin-19 / genetics. Neoplastic Cells, Circulating / chemistry. Pancreatic Neoplasms / diagnosis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Bone Marrow / pathology. Humans. Peritoneal Lavage. RNA, Messenger / analysis. RNA, Messenger / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Veroff Pathol. 1993;142:1-197 [7504860.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Oct;13(4):663-74, ix [15350940.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Surgery. 1995 Sep;118(3):472-8 [7652681.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):626-30 [7559078.001]
  • [Cites] Pancreas. 1997 Mar;14(2):126-32 [9057184.001]
  • [Cites] JAMA. 1965 Sep 27;193(13):1087-90 [5896869.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):559-68 [1372155.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1419-24 [7688814.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):384-7 [8406311.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):408-11 [9247282.001]
  • [Cites] Lab Invest. 1997 Sep;77(3):213-20 [9314945.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):361-5 [9565114.001]
  • [Cites] J Pathol. 1998 Mar;184(3):234-9 [9614373.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):119-25 [9935241.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):593-9 [10100711.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1813-20 [10206298.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):532-9 [10228857.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:111-3 [10436799.001]
  • [Cites] World J Surg. 1999 Sep;23(9):888-91 [10449815.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):669-76 [16136352.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2840-7 [10537351.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2974-7 [10576385.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):95-101 [10687736.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1037-44 [10699892.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):15-20 [11197354.001]
  • [Cites] Surgery. 2001 May;129(5):537-46 [11331445.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):695-702 [11345833.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):109-17 [11561750.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1351-61 [11598148.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Eur J Surg Oncol. 2001 Dec;27(8):740-5 [11735170.001]
  • [Cites] Br J Surg. 2002 May;89(5):573-8 [11972546.001]
  • [Cites] Cancer. 2002 May 1;94(9):2511-6 [12015777.001]
  • [Cites] Pancreatology. 2002;2(2):79-88 [12123098.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Am Surg. 2004 Mar;70(3):208-13; discussion 213-4 [15055843.001]
  • [Cites] Pancreas. 2004 Apr;28(3):263-7 [15084968.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):330-5 [8168992.001]
  • (PMID = 17226905.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC4065954
  •  go-up   go-down


96. Muramatsu K, Hashimoto T, Seto S, Gondo T, Ihara K, Taguchi T: Low-grade central osteosarcoma mimicking fibrous dysplasia: a report of two cases. Arch Orthop Trauma Surg; 2008 Jan;128(1):11-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 24-year-old woman diagnosed as fibrous dysplasia was treated with intra-lesional excision and curettage of the tumor but tumor recurred at 4 months after surgery.
  • A 57-year-old man diagnosed as central osteosarcoma was treated with wide excision of the tumor, followed by reconstruction with the vascularized fibula graft combined with an autogenous irradiated bone graft.
  • Because of the difficulty in distinguishing low-grade central osteosarcoma from a benign lesion, open biopsy is needed to obtain a large tumor sample.
  • Careful clinical and pathological evaluation is required to obtain a definite diagnosis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Femoral Neoplasms / diagnosis. Fibrous Dysplasia of Bone / diagnosis. Osteosarcoma / diagnosis. Tibia
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203284.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Vaz G, Richard A, Guyen O, Bejui-Hugues J, Carret JP: [Desmoplastic fibroma or bone desmoid tumor: two cases]. Rev Chir Orthop Reparatrice Appar Mot; 2005 Dec;91(8):782-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic fibroma or bone desmoid tumor: two cases].
  • [Transliterated title] Le fibrome desmoplastique ou fibrome desmoïde osseux: à propos de 2 nouveaux cas d'une tumeur osseuse rare.
  • Desmoplastic fibroma or desmoid bone tumor is a rare tumor described for the first time by Jaffe in 1958.
  • It accounts for 0.1 to 0.3% of all benign bone tumors.
  • Histology is required for certain diagnosis of desmoplastic fibroma.
  • The tumor is composed of sparse fibroblasts in a rich background of collagen fibers, a histological presentation exactly the same as soft tissue desmoid fibroma.
  • The observations illustrate the radiological diagnosis.
  • MRI was used to search for local extension in bone or soft tissues.
  • Biopsy is necessary to confirm the diagnosis.
  • Surgery is the optimal treatment, with tumor resection as wide as possible depending on the localization.
  • [MeSH-major] Bone Neoplasms. Fibroma, Desmoplastic. Fibromatosis, Aggressive. Pelvic Bones. Tibia

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553001.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Fenichel I, Garniack A, Morag B, Palti R, Salai M: Percutaneous CT-guided curettage of osteoid osteoma with histological confirmation: a retrospective study and review of the literature. Int Orthop; 2006 Apr;30(2):139-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma is a benign bone tumour usually occurring in young individuals (10-30 years).
  • In the past, surgery was performed in an "open" fashion and the nidus had to be removed with a bone block.
  • The diagnosis was histologically confirmed in 14 cases out of 18 (77%).
  • The use of a cannulated drill and a cannulated curette facilitates efficient removal of the tumour and procurement of tissue for diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rofo. 2001 Aug;173(8):708-13 [11570240.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Nov-Dec;19(10):1955-8 [9874556.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):76-85 [3956019.001]
  • [Cites] J Pediatr Orthop. 1990 Jul-Aug;10(4):510-3 [2358492.001]
  • [Cites] J Formos Med Assoc. 1990 May;89(5):366-72 [1977846.001]
  • [Cites] J Pediatr Orthop. 1990 Nov-Dec;10(6):800-4 [2250070.001]
  • [Cites] Radiology. 1991 Oct;181(1):269-71 [1887046.001]
  • [Cites] Rofo. 1991 Dec;155(6):532-7 [1764595.001]
  • [Cites] Radiology. 1992 Apr;183(1):29-33 [1549690.001]
  • [Cites] Radiology. 1993 Aug;188(2):541-7 [8327712.001]
  • [Cites] Rev Rhum Ed Fr. 1993 Jan;60(1):28-36 [8242023.001]
  • [Cites] Radiology. 1994 Apr;191(1):217-23 [8134575.001]
  • [Cites] Pediatr Radiol. 1994;24(3):185-8 [7936795.001]
  • [Cites] Clin Orthop Relat Res. 1995 Jan;(310):170-5 [7641435.001]
  • [Cites] Radiol Med. 1995 Jul-Aug;90(1-2):84-7 [7569103.001]
  • [Cites] Radiology. 1995 Nov;197(2):451-4 [7480692.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1995;81(4):317-25 [8560001.001]
  • [Cites] J Radiol. 1996 Jan;77(1):37-40 [8815223.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1996;82(8):737-42 [9097860.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Apr 18;122(16):507-10 [9162624.001]
  • [Cites] Unfallchirurg. 1997 Jul;100(7):536-40 [9340778.001]
  • [Cites] Radiol Clin North Am. 1998 May;36(3):559-66 [9597073.001]
  • [Cites] Radiology. 1984 Nov;153(2):543-4 [6484185.001]
  • (PMID = 16474938.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC2532079
  •  go-up   go-down


99. Slesarenko YA, Sampson SP, Gould ES, Dagum AB: Recurrent enchondroma protuberans: a case report. J Hand Surg Am; 2005 Nov;30(6):1318-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enchondroma protuberans is a rare benign tumor.
  • [MeSH-major] Bone Neoplasms / pathology. Chondroma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Fractures, Bone / etiology. Fractures, Bone / pathology. Fractures, Bone / surgery. Humans. Male. Metacarpal Bones / injuries. Metacarpal Bones / pathology. Metacarpal Bones / surgery

  • Genetic Alliance. consumer health - Enchondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344196.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Cantwell CP, Scanlon T, Dudeney S, O'Byrne J, Eustace S: CT guided radiofrequency ablation of intra-articular osteoid osteoma of the hip. Ir J Med Sci; 2005 Jul-Sep;174(3):97-9
MedlinePlus Health Information. consumer health - Joint Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteoid osteoma is a painful benign bone tumour.
  • Image guided radiofrequency ablation can be clinically applied to ablate the tumour in a minimally invasive manner.
  • [MeSH-major] Bone Neoplasms / surgery. Catheter Ablation. Hip / physiopathology. Joint Diseases / therapy. Osteoma, Osteoid / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Jul;224(1):82-6 [12091665.001]
  • [Cites] Clin Imaging. 2000 Jan-Feb;24(1):19-27 [11120413.001]
  • [Cites] Radiology. 2003 Oct;229(1):171-5 [12944597.001]
  • [Cites] J Bone Joint Surg Br. 2001 Apr;83(3):391-6 [11341426.001]
  • [Cites] Radiology. 2003 Jan;226(1):125-8 [12511680.001]
  • [Cites] Radiology. 1994 Apr;191(1):217-23 [8134575.001]
  • [Cites] Skeletal Radiol. 2002 Oct;31(10):559-69 [12324824.001]
  • (PMID = 16285350.001).
  • [ISSN] 0021-1265
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement